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Macrophages are required to show plasticity in how they react to their 
microenvironment and orchestrate an inflammatory response. With such an integral 
role in human immunity, aberrant macrophage function can directly contribute to a 
variety of pathologies: from driving chronic inflammation to a compromised 
clearance of invading pathogens. Although there are pharmaceutical opportunities 
to restore alveolar macrophage function in disease, there still remains a challenge to 
truly profile their activity in situ. The use of optical endomicroscopy - a non-invasive, 
fibre-optic imaging platform capable of accessing the alveolar space, may be used 
in combination with optical probes to profile alveolar macrophage activity in their 
native environment.  
Work outlined in this thesis covers the characterisation of a human monocyte-
derived macrophage model phenotype, performed using gold-standard in vitro 
systems including flow cytometric analysis of receptor expression and phagocytic 
activity. The work then moves on to explore alternative ways of optically profiling 
macrophages that may have clinical applications.  
An optical probe was synthesised to target the mannose receptor, a cell-surface 
receptor expressed on macrophages, using a camelid nanobody fragment as a 
targeting ligand. Initial characterisation showed cell-type specificity of the probe 
towards macrophages. While labelling appeared to be via active internalisation by 
cells, more evidence is required to determine if this probe interacts specifically with 
the mannose receptor target.  
A novel form of optical endomicroscopy was used to explore imaging macrophages, 
label-free, via their auto-fluorescent emission spectra. This was to distinguish 
macrophages following internalisation of a fluorescent target, without further 
labelling required to image negative cells. Initial imaging showed that in vitro 
monocyte-derived macrophages did not fluoresce brightly enough to be imaged 
label-free, though it is expected that primary lung macrophages – particularly from 
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COPD patients who smoke – would be sufficiently bright enough to profile with this 
technique.  
Ultimately this work will be the foundation to profiling primary alveolar 
macrophages in health and disease. Using optical endomicroscopic imaging systems 
with optical probes for markers of cell phenotype, as well as other label-free 
methods in development, there is potential to profile the activity of alveolar 
macrophages directly in the alveolar space of the human lung and monitor 





The macrophage immune cell is a key actor in how the human body responds to 
invading bacteria and control inflammation. Macrophages can recognise the 
bacteria that pose a threat and recruit other parts of the immune system to clear it. 
This is particularly important in the airways of the lung, as macrophages in this 
region are the first cells to come into contact with bacteria (and other debris) we 
breathe in. 
The work in this thesis first describes the use of human monocyte immune cells 
being taken outside of the body and cultured into macrophages. This model is used 
to re-affirm standard techniques of interrogating the activity of macrophages, and 
how they respond to drugs. The work then moves onto more novel methods of 
interrogating macrophage activity, with a focus on being able to carry this out inside 
the human lung.  
One method involves the use of a fluorescent antibody fragment as a probe to 
specifically target human macrophages by binding to a marker on the surface of the 
cells. While this novel probe appears to specifically label macrophages over other 
types of cells in the human lung, more work is required to show it binds to its 
intended target on the surface of macrophages.  
Another method involves using a microscope connected to imaging fibres small 
enough to reach down into the lung to capture macrophages in their native 
environment. Macrophages in the lung can emit their own colour of fluorescent light 
which can be detected by the microscope. In order to show how this microscope 
could be used to interrogate macrophage activity in the lung, human macrophages 
were fed labelled targets (either bacteria or dying immune cells) that emitted light 
in a slightly different colour. Therefore, the microscope would be able to distinguish 
between macrophages that were capable of eating and those that weren’t based on 
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Chapter One: Introduction 
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1.1 A Brief Overview of Inflammation 
 
Inflammation is an incredibly well conserved mechanism that ensures the human 
body can react effectively to any harmful stimuli 1. Beneath the outward-facing signs 
of calor, dolor, rubor, and tumor, there are a host of interactions taking place at the 
cellular and molecular level to recognise the cause of harm, eliminate it, and begin 
repair 1.  
  
At the outset of inflammation, neutrophils are recruited in large numbers to the site 
of injury 2. Neutrophils represent the most common leukocyte population in the 
body and are key to an inflammatory response. As first responders to environmental 
challenges, they can identify and ingest foreign material 2. Neutrophils can also 
release an arsenal of cytotoxic products such as reactive oxygen species (ROS) to 
neutralise pathogens in the environment 3. In addition to neutrophils, monocytes are 
recruited to the inflammatory site from the circulation 4. These monocytes 
differentiate into macrophages to drive forward the inflammatory response with the 
production of pro-inflammatory mediators, ranging from tumour necrosis factor  
(TNF), interleukin-1 (IL-1) and nitric oxide (NO), each facilitating anti-microbial 
activity 5. Production of interleukin-12 and 13 signal the start of T cell activation (Th1 
and Th13)  and differentiation, and a shift to adaptive immunity 6.  
 
At some point during inflammation, a switch must be flipped: all the processes 
initiated at the onset of the inflammatory response must also be dampened in order 
for the tissue to return to a form of homeostasis. This clean-up operation entails the 
removal of pro-inflammatory cytokines (so that there is not a continuation of 
immune cell activation), cessation in signals for further immune cell recruitment 
(through stopping chemokine production), as well as clearance of already-
extravasated cells that are no longer required 7. Often the clearance of extravasated 
cells, mostly neutrophils, involves the onset of apoptosis, followed by efferocytosis 
by macrophages 8. There is also the production of WNT ligands, transforming 
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growth factor beta (TGF-ß), and soluble mediators such as prostaglandins to 
commence tissue repair in the environment from any collateral damage that 
occurred during the inflammatory phase 9,10,11.  
 
1.2 The Role of Macrophages in Inflammation 
 
Macrophages are a member of the mononuclear phagocyte system which also 
encompasses monocytes and dendritic cells. The longstanding hypothesis of 
macrophage origin had been they arose from peripheral blood monocyte 
differentiation 4. Circulating monocytes in the blood entered tissues when recruited 
during inflammation and differentiated into macrophages in the presence of growth 
factors (M-CSF, GM-CSF) and cytokines (interferon-gamma, IL-4) 12. More recent 
studies have shown evidence for there being populations of tissue-resident 
macrophages present even before birth, developing in the yolk sac during embryonic 
development 13. These populations of macrophages are also believed to have the 
capacity for self-renewal 14. 
 
While the nomenclature has moved on in recent years, historically the activated 
states of macrophages were defined under two opposing forms: classical “M1” 
activation and alternative “M2” activation 15. The M1 state is considered the pro-
inflammatory form macrophages can take. This has typically been characterised as 
macrophages producing proinflammatory cytokines (TNF-α, IL-1) and reactive 
oxygen and nitrogen species, as well as being closely associated with promoting a 
Th1 immune response through antigen presentation 6. This portrayed M1 
macrophages as also having strong microbicidal and tumoricidal capabilities. 
Activation of macrophages into the M1 phenotype can be through stimulation of 
inflammatory cytokines such as interferon-γ (IFN and TNF-α), or from exposure to 
microbial products like lipopolysaccharide (LPS) 16.  
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By contrast, M2 macrophages represent the pro-restorative features also attributed 
to macrophages. This includes functions associated with tissue remodelling and 
stimulating the Th2 response 15. The typical stimulant associated with M2 activation 
is interleukin-4 (IL-4) 17. The metabolic functions of M2 macrophages also distinguish 
them from M1 macrophages: rather than metabolising arginine to nitric oxide (an 
M1 trait), M2 cells metabolise the amino acid into ornithine and polyamines for 
tissue repair purposes 18,19. 
 
The M1/M2 dichotomy appealed to the notion that inflammation vacillates between 
two overarching states: activation and resolution. Therefore macrophages were 
given defined states that reflected this. However, over the years it became clearer 
that macrophages do not fall into one of these two rigid states. Instead, M1/M2 
became classed as two polarised states, between which is an entire spectrum of 
activation that macrophages could adopt. In addition to this, further evidence 
showed that tissue resident macrophages would adopt their own unique phenotype, 
comprising a combination of markers from the M1/M2 dichotomy 20,21. This makes 
intuitive sense, as there would likely be an assortment of stimulants in a given 
microenvironment that seek to polarise macrophages one way or another. 
Therefore, as the tissue microenvironment govern the ultimate phenotype of 
resident macrophages, they were characterised as unique tissue-resident 
populations depending on where in the body they reside: Langerhans cells in the 
skin, Kupffer cells in the liver, microglia within the brain, , peritoneal macrophages 










Figure 1.1 The alternate pathways of macrophage polarisations and the biomarkers associated with the two ends 
of the polarised spectrum. From Arora et al. (2018) 23 
 
1.2.1 Macrophage Phagocytosis: “the big eater” 
 
The professional phagocyte system comprises of: macrophages, dendritic cells, 
monocytes, neutrophils, and eosinophils 24. Metchnikov gave macrophages their 
name to describe one of their classic functions in immunity 25. The key role for “the 
big eater” is to orchestrate the response to foreign material by first engulfing it. 
Phagocytosis is the integral process that facilitates the programmed responses to 
what material a macrophage has come into contact with, therefore what type of 
process is required 26.  
 
Phagocytosis is a receptor-mediated event 27. Plasma membrane receptors on the 
surface of the macrophage dictate the specific nature of phagocytosis, as each will 
have specific binding affinity for mediating phagocytosis of different target ligands 
(Figure 1.2A). Microbial ligands for phagocytic recognition are proteins and lipids 
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that distinguish the microbe as foreign, such as lipopolysaccharide (LPS) and 
lipoteichoic acids 27. These are commonly known as pathogen-associated molecular 
patterns (PAMP) 28. Toll-like receptors on the surface of macrophages aid in the  
recognition of PAMPs on the surface of microbes, while other pattern recognition 
receptors (PRR) help recognise damage associated molecular patterns (DAMP) on 
self-tissue 29,30. For example, sugars such as glucan that are present on pathogens 
are recognised by the PRR Dectin-1, while LPS present on the surface of gram-
negative bacteria is recognised by the Scavenger Receptor A 31,32. The scavenger 
receptor A, as well as other PRRs such as MARCO, are also responsible for the 
clearance of other waste in the local environment such as oxidised lipids that, if left, 
would trigger unwarranted inflammation 33. Microbes and other foreign bodies can 
be targeted by soluble molecules in the blood, such as immunoglobulins and 
complement, that are recognisied by opsonic receptors that stimulate phagocytosis 
34. Fcγ receptors (FcγRI, FcγRIIA, FcγRIIB, FcγRIIC, FcγRIIIA, and FcγRIIIB) on 
macrophages bind to the Fc portion of IgG antibodies 35. Upon binding, activated 
FcγRs stimulate immunoreceptor tyrosine-based activation or inhibitory motifs 
(ITAM) which in turn activate phosphatidylinositol 3-kinases (PI3K)  that activate 
GTPases to initiate phagocytosis 34. 
 
On apoptotic cells, certain phospholipids such as phosphatidylserine (PS) serve as 
“eat me” signals to macrophages, marking the apoptotic cell for clearance 36. A 
number of receptors can recognise exposed PS to elicit efferocytosis- the 
internalisation of apoptotic cells. The T cell immunoglobulin mucin family (TIM), 
BAI1, and Stabilin-2 can directly interact with PS on apoptotic cells, while the TAM 
phagocytic receptor family (Tyro3, Axl, Mer) bind to bridging molecules protein S 
and Gas6 to facilitate efferocytosis 37,38,39,40.  
 
Once a target has been internalised, an early phagosome vacuole is formed within 
the cytoplasm of the macrophage, to compartmentalise the ingested material 
(Figure 1.2B) 41. This phagosome subsequently fuses with lysosomes and other 
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products of the endoplasmic reticulum and Golgi network to form a secondary 
phagolysosome 42. Acidification of the phagolysosome reduces the pH to ~4.5 to 





Figure 1.2 A) A selection of cell surface receptors expressed on macrophages that mediate phagocytosis of 
microbes and other foreign material, and apoptotic bodies. B) Overview of the phagocytic pathway. Adapted 




1.3 Alveolar Macrophages 
 
Every day the human lung faces a number of environmental challenges: from 
inhalation of infectious agents to any other potentially harmful particulate matter. 
The alveolar-capillary barrier, the site of gas exchange in the lung, is the key site 
where potential pathogens or particles can gain access to the bloodstream. 
Maintaining control of this barrier is essential to not only preventing infections, but 
to maintain inflammatory homeostasis in the lung, including the prevention of 
excess inflammation that could also hinder gas exchange 44. The orchestrator of 
inflammatory responses in this space is the cell that first comes into contact with 
inhaled material: the alveolar macrophage (AM). 
 
AMs are a unique and important population of resident macrophages within the 
body’s immune network 45. Over 90% of the pulmonary leucocyte population are 
AMs 46. While circulating monocytes can differentiate into AM-like cells to fulfill this 
specialised role, there is evidence to suggest a bespoke AM population is present 
soon after birth 47. AMs can reside for a long time in the alveolar space, lasting weeks 
to months 48.  In some cases, there has been evidence of cigarette products being 
present within AMs years after cessation of smoking, further highlighting their long 
life-span 49. Resident AMs have also shown a stable capacity for self-renewal 14.  
 
There appears to be an important role for GM-CSF in maintaining the AM population 
in the lung 50. Higher levels of GM-CSF enable migrating monocytes to the lung to 
differentiate into the unique AM phenotype, including adhesion to the alveolar walls 
51. The alveolar epithelial cell wall provides a continuous source of GM-CSF 52. In 
addition to GM-CSF, the nuclear receptor PPAR-γ has also been shown as a key 
regulator of alveolar macrophage differentiation and maintenance, something 
which is more unique AMs compared to other tissue resident populations 53,54. This 
reveals that alveolar macrophages, like other tissue macrophages, possess a unique 
transcriptional program in order to regulate their unique phenotype 55. 
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Some have suggested that the quiescent state of AMs revolves around a 
predominantly anti-inflammatory phenotype, as depletion of these cells in animal 
models has resulted in excessive production of pro-inflammatory mediators 56. AMs 
are thought to show a reduced response to foreign material at first. This is 
exemplified by low basal expression of CD86 (a pro-inflammatory, co-stimulatory 
molecule for T cell activation) on the AM surface 57. It has also been established that 
AMs are comparatively poor at antigen presentation to T cells as well as having a 
limited capacity for respiratory burst 58,59. These factors contribute to minimal 
responses of unstimulated AM to particulate material they encounter. 
 
AMs possess a number of mechanisms to non-specifically target foreign material in 
the lung. This involves the expression of PRRs and scavenger receptors 60. This form 
of response to microorganisms is capable of countering up to 109 intra-tracheal 
bacteria before further engagement of the immune system is required 61. Two 
receptors that are closely associated with the AM phenotype are the mannose 
receptor (MR) and MARCO 62. These receptors aid in the recognition of unopsonised 
bacteria, by binding to sugars (mannose, fucose, N-Acetylglucosamine) present on 
these pathogens 62. The oxidative stress that AMs encounter in the presence of 
pathogens leads to the expression of TLR4 on their surface, which in turn stimulates 
expression of other TLRs 63,64. This then endows the AMs with a greater phagocytic 
capacity and supports pro-inflammatory cytokine production 65,66.  
 
As sentinels of the alveolar-capillary barrier, AMs are charged with walking an 
inflammatory tightrope in their resident environment. They must show a higher 
tolerance to foreign material than is expected of other tissue macrophages, while 
also being proficient in inciting and dampening inflammatory responses efficiently 
enough to avoid damage to lung tissue. With so many roles to play, aberration in one 
or more of their functions quickly implicates AMs in lung pathology.  
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1.3.1 Alveolar macrophages in disease: COPD as a case example 
 
Often associated as a smoker’s disease, chronic obstructive pulmonary disease 
(COPD) is an increasingly threatening inflammatory disease throughout the world. 
In the coming years, COPD is expected to become the third leading cause of death 
globally 67. Back in 2010, the economic costs of treating COPD topped $2.1 trillion, 
half of which from developing nations 68. The pathology of COPD is characterised as 
progressive lung function decline- caused by aberrant and persistent inflammation 
in response to cigarette smoke exposure and other environmental pollutants 69. 
 
AMs are closely linked to the pathology of COPD, due to defects in the cell 
phenotype that contribute to the common hallmarks of COPD (persistent 
inflammation and recurring infections) 70. There is an increase in AM cell number 
during COPD 71. The increased numbers likely stem from aberrant chemokine 
production in the airways, such as MCP-1, causing continual recruitment of 
monocytes to the alveolar space 72. This is supported by evidence of increased 
amounts of MCP-1 being present in the sputum of COPD patients 73. Other factors 
possibly contributing to increased AM numbers in COPD are expansion of local 
proliferation in the alveolar space with prolonged survival 74.  
 
While COPD appears to increase the number of AMs present in the lung, 
macrophages show little capacity at relieving inflammatory symptoms or preventing 
recurring infection. It is now well established that there are clear phagocytic defects 
in AMs during COPD 75. Studies have shown that alveolar macrophages retrieved 
from broncho-alveolar lavage (BAL) fluid of COPD patients, as well as macrophages 
cultured in vitro from monocytes retrieved from the blood of COPD patients, show a 
diminished ability to phagocytose pathogens often associated with infections during 
COPD, including: Haemophilus influenzae, Pseudomonas aeruginosa 
and Streptococcus pneumoniae 75,76. Further studies on AM function in COPD show 
that phagocytic dysfunction is not limited to microbial clearance, as AM 
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efferocytosis is also impaired during COPD, resulting in a lack of apoptotic cell 
clearance in the alveolar space 77. Interestingly, the AM phagocytic defect in COPD 
does not extend to inert particle clearance, which relies more on scavenger receptor 
activity 76,78.  
 
While it has been hypothesised that possible reasons for defective AM phagocytosis 
in COPD may be due to diminished PAMP recognition or expression of phagocytic 
receptors, there is limited evidence to support this 79. One study found that cigarette 
exposure (which is often the case in COPD) decreased TLR3 expression, though no 
changes were found for other TLRs 80. Another study showed that COPD had little 
impact on the expression of phagocytic receptors, such as CD44, CD36, CD51, CD61, 
CD14, and CR3 81. The same study did find some effect on other receptor expression 
in COPD, as there was a reduction in HLA-DR and CD80 81. In considering receptor 
expression as a marker for COPD, one study did find that the scavenger receptor 
CD163 is predominantly expressed on isolated AMs from the BAL of COPD patients 
82. Another reason for poor phagocytic activity could be continual AM exposure to 
oxidative stress, due to chronic exposure to cigarette smoke 78. Sustained oxidative 
stress can lead to AM deficiency of both bacterial clearance and apoptotic cell 
removal 78,83.  Although, one study has shown that AM phagocytic defects are not 
limited to active smokers 83. 
 
Studies have focussed on elucidating the phenotype of AMs during COPD. There is 
a rise in production of chemokines that recruit more immune cell types, for example 
interleukin-8 (IL-8) has found to be elevated in COPD airways 84. There is also a 
characteristic cytokine profile in COPD that can be attributed to AMs, such as 
elevated levels of the pro-inflammatory mediator TNF-α found in the sputum of 
COPD patients 84. In addition, there is increased production of matrix 
metalloproteases and cathepsins, which likely contribute to persistent remodelling 
of lung tissue 85. This profile likely stems from altered regulation of transcription 
factors that influence AM cytokine production. For example, the activation of NF-kB 
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- which plays a well-established role in the production of pro-inflammatory 
mediators including TNF and iNOS – correlates to exacerbations of COPD 86. 
 
Reviewing the cytokine and receptor profiles of AMs during COPD reveals how 
macrophages in disease can present as antithetical to the linear spectrum of 
activated states. While AMs show increased expression of pro-inflammatory 
cytokine products, they also express receptors and other markers associated with an 
M2, pro-resolution state. AMs appear to be trapped in facilitating the vicious cycle 
that occurs during COPD: incapable of resolving inflammation in the airways, the 
AMs maintain a pro-resolving phenotype in their continued attempts to recapture 
some form of lung homeostasis. This in turn leaves the AMs ill-prepared for recurring 
infections that exacerbate the oxidative stress in the microenvironment, triggering 
pro-inflammatory mediators that recruit even more immune cells which won’t be 
effectively cleared- perpetuating the inflammatory cycle (Figure 1.3).   
 
The current treatment for COPD largely focuses on alleviating the restriction airflow 
in the disease 87. There is still a gap in COPD therapy that effectively slows down the 
decline of lung function or restore activities integral to recapturing the inflammatory 




different pathologies, there would be new avenues opened up for personalised 
medicine in diseases where macrophages are implicated.  
 
Nanoparticle-based approaches have been explored to therapeutically manipulate 
macrophage function  89,90,91. Use of nanoparticles has largely focussed on improving 
the specificity of molecular imaging techniques for detecting macrophages. For 
example, one study used a radiolabelled nanoparticle to be specifically taken up by 
inflammatory monocytes and macrophages in atherosclerotic plaques, while also 
showing promise as a marker for cell responses to anti-inflammatory treatment 92. 
Another study developed liposomes that present phosphatidylserine to mimic 
apoptotic cells in order to encourage macrophages to adopt an anti-inflammatory 
phenotype 93. In vitro and some in vivo studies in mice showed these nanoparticles 
were taken up by macrophages in atherosclerosis models 93. These macrophages 
subsequently showed upregulation of CD206 (the mannose receptor) and 
downregulation of CD86, aligning with a change in phenotype 93.  Other strategies 
using nanoparticles to modulate macrophage activity have been deployed to limit 
the production of pro-inflammatory mediators, such as TNF-a, cyclooxygenase-2 
(COX-2) and reactive oxygen species (ROS) 94,95,96. These strategies highlight the 
potential for more directed macrophage therapy, focussing on specific products of 
their phenotype rather than general targeting of cells that could have unintended 
consequences 89.  
 
In the context of COPD, macrophage therapy has previously struggled to make 
headway. An abundance of pro-inflammatory mediators stemming from AMs in 
COPD contribute to the pathology, but the use of corticosteroids – a mainstay anti-
inflammatory therapy – have shown little effect in suppressing these mediators 97,98. 
One study found that insensitivity to corticosteroids – specifically dexamethasone - 
was specific to COPD AMs when compared to AMs from regular smokers 99.  
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As oxidative stress is postulated to be influential on AM function during COPD, a 
range of antioxidant therapies have been explored to restore lost activities. Some 
studies have directed efforts to the activation of transcription factor nuclear 
erythroid–related factor 2 (Nrf2), as it is responsible for the transcription of anti-
oxidant proteins 100,101. Nrf2 is stimulated during oxidative stress to dissociate from 
its inhibitor (Keap1) and is then translocated to the nucleus where it binds to 
antioxidant response elements (ARE) 102. This process has been shown to be 
disrupted in mice models following exposure to cigarette smoke, as well as a decline 
in its transcriptional activity has been confirmed in AMs from COPD patients 103,104. 
Treatment with sulforaphane, a natural agonist for Nrf2, initially improved 
phagocytosis by AMs in a COPD mouse model and in isolated AMs from COPD 
patients 100. This restoration in activity coincided with increased expression of the 
MARCO scavenger receptor and anti-oxidant elements 100. Further studies have 
shown that defective phagocytosis of opsonised bacteria is also a unique element of 
COPD, which is also treatable with Nrf2-agonists 105.  
 
A randomised clinical trial has shown that use of macrolide antibiotics, such as 
azithromycin, can reduce the number of exacerbations in COPD. Improvement in 
AM function in COPD has been shown from the use of macrolide antibiotics 106. 
Studying the effects of azithromycin on COPD AMs using in vitro methodology 
found a significant improvement to AM phagocytic activity following azithromycin 
treatment 107. The improvement in AM activity coincided with changes in receptor 
expression. Expression of CD206 (the mannose receptor) has previously been shown 
to be reduced during COPD, though expression was increased by up to 50% 
following azithromycin treatment 107. Multiple studies present conflicting data on 
the actual effect azithromycin treatment has on COPD patient cohorts, suggesting 
more detailed analysis is required to pinpoint what mechanisms by which macrolide 




1.4 Optical Molecular Imaging  
 
Molecular imaging provides a window to the inside of living systems. Depending on 
the spatial resolution of the system involved, it is possible to detect, characterise, 
even measure biological processes taking place, right down to the cellular level with 
micromolar resolutions 109. Improvement in the resolution is directly proportional to 
the level of detailed information that can be observed: this can range from simple 
anatomical structures to cellular interactions 110. Development of new generations 
of molecular imaging technology widens the possibility of identifying new targets 
for pathology as well as improving our understanding of mechanisms that take place 
in health and disease 111. A priority of modern imaging systems is to ensure they are 
non-invasive, whilst maintaining a resolution that is high enough to deliver the 
information required. Effective implementation of such devices would bring a direct 
improvement to clinical medicine as well as basic scientific research.  
 
1.4.1 Molecular imaging of the human lung 
 
One area of clinical need for improved molecular imaging is the human lung, as the 
distal regions of these organs have been challenging to study despite being such a 
critical site of infection and inflammation 112. The standard forms of imaging the 
human lung have been chest x-rays, computed tomography (CT) scanning, and 
positron emission tomography (PET) 113,114,115. Each of these imaging modalities have 
provided insight into different areas of the lung. Chest x-rays provide a two-
dimensional image as ionizing radiation would pass through the body to a detector 
on the other side 114. The resultant image resolves areas of opacity where there 
should be (such as bone) as where there shouldn’t be, as is the cased in the diseased 
lung. CT scanning built upon this by compiling multiple two dimensional images of 
the lung around a single axis of rotation, providing a reconstructed three 
dimensional image of the tissue structures 113,116. While x-rays and CT scans provide 
structural information of the lung, the development of PET scanning offered the 
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opportunity to image biological functions of the lung 115. PET imaging involves the 
use of radionucleotides as contrast agents. The radionucleotides emit a positively 
charged positron as they decay, which travels through the tissue until it collides with 
an electron. The resulting gamma rays following collision are intercepted by multiple 
detectors as they travel outside of the body; these detectors can determine the 
relative position of the positron-electron collision in the body. The functional 
imaging capabilities of PET are due to the radionucleotides acting as radioisotope 
substitutes for essential biological molecules, such as carbon and nitrogen 117. A 
prominent example is the use of 18-fluorodeoxyglucose (FDG) to act as a glucose 
substitute for PET-based imaging of glucose metabolism 118. PET advanced 
molecular imaging to go beyond just structural information, as well as highlighting 
the benefit of coupling an imaging system with an imaging agent to retrieve more 
detailed information about the body. But historically a gap remained in molecular 
imaging: the ability to resolve disease processes down to the cellular level in vivo. 
The potential to carry out microscopic imaging inside of the body, in particular the 
human lung, would be a powerful tool in efforts to improve our understanding of 
what actually happens inside of these tissues, both in disease and in health. The 
rapidly developing field of optical imaging has been making strides to achieve this 
and advance molecular imaging in the medical field even further 112.  
 
Optical imaging (OI) seeks to harness light from the visible spectrum right the way 
through to near infra-red as a means to develop systems that provide high resolution 
with in vivo imaging capabilities and clinical applications 112. Use of OI-based 
technologies should be minimally invasive and relatively low-cost. OI involves the 
absorption of light at a particular wavelength, which excites a fluorophore to emit 
fluorescent light at a slightly higher wavelength; this emitted light can subsequently 
be detected 119. The excited fluorophore can be intrinsic to biological tissue or part 
of an externally administered optical imaging probe, used in conjunction with an 
imaging system to “light up” specific cells or molecular processes, both in vitro and 
in vivo 120,112.  The source of the excitation can be from a laser or a light emitting diode 
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(LED), each capable of producing specific wavelengths of light 121. Multiplexing of 
fluorophores is a key feature of OI as different fluorophores can require different 
wavelengths of light to be excited. The stokes shift that fluorophores undergo – the 
difference in wavelength from excitation to emission of light – can be in distinct parts 
of the light spectrum. Therefore, so long as their excitation and emission spectra are 
not too close together, multiple fluorophores can be used at the same time with 
multiple excitation light sources. OI has been a mainstay in biological research, with 
the development of fluorescent proteins and fluorescently-tagged antibodies to be 
used with bench-top optical imaging systems such as flow cytometry and confocal 
laser scanning microscopy 122,123,124,125.  
 
The use of OI has been an attractive modality for in vivo imaging in humans 112. In 
comparison to radiological molecular imaging modalities described earlier in the 
chapter, optical imaging does not require the use of ionising radiation 109. The 
excitation and subsequent emission and detection of light is a fast process, while 
micrometre resolution of some optical imaging systems means imaging can be 
performed in the body to visualise cells in detail 112,109.  However, OI is not without 
its own drawbacks. One significant challenge of using OI in vivo is the lack of 
transparency in the human body; photons can be absorbed, light scattered and 
reflected back as it travels through tissue 121. This varies between tissue sites 
depending on structural differences such as their level of vascularisation and the 
density of organelles such as mitochondria 110. The use of near-infrared light (NIR) 
can partially mitigate this, as light in this spectral range of 650-900 nm has greater 
penetration through human tissue when compared to visible light further down the 
spectrum 126. This is because light in the NIR spectral range undergoes very little 
absorption by water and haemoglobin as it travels through the body 110. Another 
method to overcome light absorption is to develop detection systems that are able 
to access distal regions of the body and image in situ. This has high clinical potential 
in imaging the distal regions of the human lung, if the OI system is small enough to 
access these airways. 
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1.4.2 Optical Endomicroscopy: a cellular exploration of the alveolar space 
 
Optical microendoscopy (OEM) sought to minimise the dimensions of specific parts 
of an OI system in order to have the ability to image areas of the body that could not 
previously have been accessed. This technology has the potential to image the distal 
lung not only in situ, but also in real time 127. The in situ capabilities of OEM stem from 
utilising a flexible fibre bundle that allows excitation light to pass down. The 
excitation light is from an LED source at the proximal end of the fibre; any emitted 
light at the distal end can travel back up the fibre bundle where it meets a 
photodetector 128,129,130.  
 
One of the first commercialised optical detection systems to use fibre-based OEM 
technology was Cell-viZioTM (Mauna Kea Technologies, France). This system uses a 
laser scanning unit coupled to a fibre bundle so that fibred confocal scanning 
fluorescence microscopy (FCFM) can be carried out in the human lung, in situ, and is 
approved by the US Food and Drug Administration (FDA) 131. FCFM systems like Cell-
viZioTM are able to take advantage of the benefits confocal laser scanning microscopy 
offers to OI. That is, the ability to perform high resolution imaging across a single 
focal plane, eliminating out of focus light that could disturb the field of view (FOV) 
132. Some groups have used FCFM to image structures such as bronchial tissue, which 
can be fluorescently excited 488nm (using blue excitation light) due to the 
autofluorescence of the elastin in this tissue (Figure 1.4)128. Further work has shown 
the high degree of inter-observer reliability with this form of optical imaging 127. In 
addition to FCFM, widefield fibre-based OEM system have since been developed 





1.4.3 Optical Probes for imaging macrophages  
 
As with other forms of molecular imaging, OEM can be aligned with compatible 
probes to enhance the specificity and sensitivity of imaging, as well as tracking of 
dynamic biological events. These probes typically consist of a ligand with a specific 
affinity for a molecular target, conjugated to a fluorescent reporter 133. The 
application of clinically translatable optical probes together with OEM has been 
demonstrated previously by using antimicrobial peptides conjugated to fluorescent 
reporters to label bacteria and activated neutrophils in lung tissue 134,135,136. 
 
The probes must be able to function suitably in the dynamic environment of human 
tissue and amplify their signal to be detected by optical imaging systems 111. 
Background noise can be an issue for detecting fluorescent molecular probes, which 
can be exacerbated by unbound probes contributing to the poor signal to noise ratio 
111.  
 
The ligand of optical probes can be specific to a target cell; this is often achieved via 
targeting surface receptors that are uniquely expressed by specific cell populations. 
The use of optical probes to label macrophages has been considered as expression 
of receptors on the surface of macrophages can indicate their activation state and 
activity. Targeting these receptors for optical labelling may provide phenotypic 
information about a macrophage in addition to labelling the cell. One example of 
this involves targeting the folate receptor 137. This receptor is used for the uptake of 
folic acid, an essential nutrient for amino acid synthesis.138 Cells increasing their 
metabolic rate upregulate the folate receptor, likely to increase folate uptake to 
support the glycolytic pathway 139. Increased activity of the folate receptor beta 
isoform has been reported on the surface of macrophages following stimulation with 
LPS, a common pathogen associated molecular pattern (PAMP) 137. In one study, an 
optical probe for folate receptor – via fluorescently conjugated folic acid - was 
developed for targeting macrophage populations that may be associated with pro-
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inflammatory activity and contributing to acute lung inflammation 137. Another 
study sought to use a fluorescent folic acid conjugate to target inflammatory 
macrophages, while simultaneously using a fluorescent mannose conjugate 
(targeting the mannose receptor) to target anti-inflammatory macrophages 140. 
They used an in vitro infection model to demonstrate multiplexing of these optical 
probes to stratify the phenotypic changes in macrophages post-stimulation 140.  
 
Development of other macrophage-targeting probes have involved tracking the 
activity of the cell. For example, a library of probes was synthesised with specific 
cleavage sites for Hydrogen peroxide (H2O2), a common ROS produced by 
macrophages 141. The chemical cleavage by H2O2 on the probe changes the electron 
transfer properties, resulting in fluorophore emission. This is an example of a 
“smartprobe”: probes that dynamically change their fluorescent properties upon 
interaction with their target. The benefit of using smartprobes is their signal is only 
amplified when interacting with a target 142. Background noise can be an issue for 
detecting fluorescent molecular probes, which can be exacerbated by unbound 
probes contributing to the noise 111. The use of smartprobes can mitigate this issue 
142. Novel smartprobes have also been synthesised to track the phagocytic activity 
of macrophages. For example, one study developed a pH-sensitive fluorophore 
scaffold that could be selectively internalised by macrophages 143. Emission of 
fluorescence by the probe coincides with a drop in pH, an indication of 
phagolysosome maturation 144.  
 
The development of fluorescent probes to target macrophages carry a lot of 
potential to couple these imaging agents with OEM systems that can take forward 
their macrophage targeting to in situ settings. One study has already used a smart 
fluorophore to detect myeloperoxidase activity in macrophages of rat models of 
acute lung injury 145. There is however limited use of combining fluorescent probes 
for macrophages with OEM systems. With increased efforts to marry the two, the 
potential for profiling macrophages in situ rises inexorably. To have a library of 
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probes that can track the activity or phenotypic state of macrophages – in the 




1.5 Hypotheses and Aims 
 
The introduction to this thesis provides an overview of key elements of 
inflammation, with a particular focus on the activity of alveolar macrophages and 
how aberrant function is implicated in lung diseases. While there is an active field of 
research studying how to effectively profile alveolar macrophages and 
therapeutically modulate their activity, there still remains a limited understanding 
of how AMs function in situ, and whether therapeutic drugs work as effectively in situ 
as they do using in vitro methodologies.  
 
In light of this, the aims of my research have been to establish novel ways of profiling 
macrophages that could be performed in the alveolar space. The overarching 
hypothesis has been that surface receptor probes and optical endomicroscopy 
imaging systems can be used to profile alveolar macrophages in situ. 
 
The work in chapter three of this thesis will cover the establishment of a cell culture 
model to differentiate monocytes into macrophages, as well as assays to profile the 
cell surface receptor phenotype and phagocytic activity.  
 
Chapter four introduces a novel fluorescent nanobody designed to selectively label 
macrophages via the mannose receptor. Studies in this chapter include biological 
characterisation of the nanobody: cell and target specificity and labelling 
characteristics.  
 
The use of fibre based optical endomicroscopy imaging platforms to profile the 
phagocytic activity of monocyte-derived macrophages and autofluorescent alveolar 























solubilised in 0.9% Baxter’s saline. The Falcon tube was gently inverted before 
allowing sedimentation to occur (25 min). Following sedimentation, the top layer of 
blood was aspirated into a fresh 50 ml falcon tube and again topped up to 50ml with 
NaCl, before being centrifuged at 350g for 6 min (brake 9, acceleration 9). Pelleted 
cells from centrifugation is then resuspended in 3 ml of 55% Percoll solution (diluted 
in HBSS). A discontinuous Percoll gradiant was set up of 55%, 68%, and 81% Percoll 
with DPBS. 3 ml of 81% Percoll was added to a 15 ml Falcon tube, followed by 3 ml 
of 68% Percoll gently layered on top dropwise to avoid mixing. The Leukocytes 
suspended in 55% Percoll were subsequently layered on top in the same fashion, 
before being centrifuged at 350g for 20 min (0 brake). Centrifugation allowed 
remaining erythrocytes to pellet at the bottom of the tube, while a suspended band 
of polymorphonuclear cells collected at the 81/68% Percoll interface and a 
suspended band of mononuclear cells collected at the 68/55% interface. Isolated cell 
populations were removed using a Pasteur pipette. The cell populations were 
counted using an NC-100 Nucleocounter Automatic Cell Counter (Chemometec, 
Denmark). The abundance of individual leukocyte populations in each isolated 
fraction was assessed using a BD FACSCalibur flow cytometer (Becton Dickinson NJ, 
USA) based on cellular side scatter for granularity and forward scatter for size. 
Cytospin slides were prepared of the cell populations to examine cell morphology 
and cell-type distribution. 2 x 105 cells were centrifuged onto glass slides using a 
Cytospin 2 centrifuge at 300 g for 3 min. The cell smear was left to air dry then stained 








2.3.2 Monocyte purification 
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Peripheral blood monocytes were isolated from the mononuclear cell fraction 
described above by using a MACS pan-monocyte separation kit (Miltenyi Biotec, 
Germany). The mononuclear layer was suspended in PBS and placed on ice for 20 
min, before being centrifuged at 350 g for 5 min (acceleration 9, brake 9) and all the 
media removed. The pelleted cells were resuspended in DPBS at a rate of 30 µl for 
every 106 cells. 10µl of Fc-blocking reagent was added for every 106 cells, as well as 
10 µl antibody cocktail at the same rate. This mixture was placed on ice for 5 min. 
Another 30 µl of DPBS was added per 106 cells, plus 20 µl of magnetic microbead 
solution at the same rate. The mixture was placed on ice for 10 min. The cell mixture 
was passed through a MACS LS column, attached to a MACS separator that created 
a magnetic field around the column. During cell mixture flow through of the column, 
non-monocytes labelled by the antibody cocktail (and subsequently labelled with 
anti-biotin microbeads) bound to the sides of the column, allowing unbound 
monocytes to be collected in a tube below the column. The collected population was 
counted again using a Nucleocounter and the scatter properties assessed using flow 
cytometry.  
 
2.3.3 Monocyte-derived macrophage culture 
 
A purified monocyte population was suspended in IMDM (pre-heated to 37 ºC) at a 
concentration of 6 x105 cells per ml. 500 µl of the cell mixture was added to individual 
wells of a 48 well polystyrene tissue culture plate, or LabTek 8-well confocal 
chamber, and incubated at 37 ºC for 1hr to allow adherence to the bottom of the 
wells. The wells were aspirated and the IMDM replaced with culture media 
containing: 500 µl IMDM (+5% autologous serum, +1% Penicillin/Streptomycin) per 
well. The adherent cells were incubated at 37 ºC, 5% CO2 for 6 days to allow for 




2.3.4 Macrophage stimulation and pharmacological treatment 
 
The use of macrophage stimulation during culture and the stimulants used is 
highlighted in figures of future chapters. Interferon-gamma (IFN) was used at a final 
concentration of 10 ng/ml and added for the final 24 hr of cell culture. 
Lipopolysaccharide (LPS) was used at a final concentration of 20ng/ml for the final 
24 hr of culture. Interleukin-4 (IL-4) was used at a final concentration of 10ng/ml for 
the final 24 hr of culture. Dexamethasone was used at a final concentration of 250 
nM and added at day 0 of the MDM culture. Sulforaphane was used at a final 
concentration of 10 µM and added for the final 18 hr of culture. 
 
2.3.5 Macrophage receptor phenotyping 
 
Isolated mononuclear cell, monocyte or differentiated MDM populations were 
seeded on 96-well round bottomed tissue culture plates and pelleted by 
centrifugation at 2000 rpm for 2 mins at 4 ºC. Cells were kept on ice for the duration 
of the assay. The media was removed and 10 μl of rabbit serum was added for 5 mins. 
Antibodies included: PE-CD11b, PE-HLA-DR, PE-CD80, PE-CD163, PE-CD206, PE-
isotype control (BD Pharminigen; all mouse IgG1 κ anti-human). Antibodies were 
diluted 1:20 from stock concentration in flow buffer (PBS + 0.5% bovine serum 
albumin (BSA).  50 µl of diluted antibodies was added for 20 min on ice, away from 
light. 100 µl of flow buffer was added and the plate was again pelleted to remove 
buffer. Pelleted cells were then suspended in 200 μl flow buffer and analysed using 
a BD FACSCalibur. Cell populations were gated on FSC/SSC and analysed for FL2+ 
(488nm laser excitation filtered through a 585nm dichroic bandpass filter) . PE 
isotype control was used to define FL2 negative events. Samples were collected in 
duplicate. For analysis performed using an Attune NxT flow cytometer, cell 
populations were also gated using FSC/SSC and analysed for staining using the YL1 
channel (561nm laser excitation filtered through a 585nm dichroic bandpass filter). 
Cell positivity for labelling was defined above isotype control labelling signal.  
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2.4 Phagocytic Assays 
 
2.4.1 Phagocytosis of polystyrene beads 
 
1 µm polystyrene microspheres (polysciences, Switzerland) were diluted in cell 
culture media described above or fresh IMDM and sonicated for 5 min. The final 
concentration used is outlined in specific figures in chapter three. The MDM culture 
media was aspirated and replaced with the microsphere suspension ± 5 µg/ml 
Cytochalasin D. The culture plate was incubated at 37 ºC, 5% CO2 for 45 min to allow 
for phagocytic interaction. Following co-culture, cells were detached by incubating 
with Trypsin+EDTA for 5 min at 37  ºC followed by pipette mixing. Cell populations 
were analysed using a BD FACSCalibur. Macrophages were gated on using FSC/SSC 
scatter properties before being analysed for FL1+ (488 nm laser excitation filtered 
through a 530nm dichroic bandpass filter) for microsphere signal. Up to 5000 gated 
events were collected with samples recorded in duplicate.  
 
2.4.2 Phagocytosis of bacteria 
 
pHrodo Green E. Coli Bioparticles were suspended in DPBS and diluted in cell culture 
media or fresh IMDM. The final concentrations used in experiments are indicated in 
figure legends of the results. The phagocytic assay setup is as described in section 
2.4.1. Following detachment post co-culture, the cell populations were analysed 
using Attune NxT flow cytometer. Macrophages were gated on using FSC/SSC 
scatter properties and doublets excluded from analysis. The gated population was 
analysed for BL2+ (488 nm laser excitation filtered through a 590nm dichroic 
bandpass filter) for pHrodo signal. Up to 5000 gated events were collected with 
samples recorded in duplicate. 
 
 
2.4.3 Efferocytosis of apoptotic neutrophils 
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Peripheral blood polymorphonuclear cells (PMN) were isolated as described in 
section 2.3.1, then cultured in a T-25 tissue culture flask at a density of 5x10
7
/ml in 
IMDM (+2% autologous serum, 1% Penicillin-Streptomycin) for 20 hr to induce 
apoptosis. This method of inducing apoptosis has been established previously to 
yield an apoptotic population of ~70% 7. The apoptotic Neutrophils were labelled 
with 1 µg/ml CellTracker Green 5-chloromethylfluorescein diacetate (CMFDA) for 30 
mins at 37 ºC, then washed and suspended in cell culture media or fresh IMDM. The 
final concentration of neutrophils for each was meant six neutrophils to one 
macrophage per condition. The phagocytic assay setup is as described in section 
2.4.1. The analysis of the cell population was either carried out using a BD 





















exciting with a 488 nm laser. A time-series was performed with 180 frames at 15 sec 
intervals (45 min total).  
 
2.4.6 Real-time spinning-disc confocal microscopy of efferocytosis 
 
Macrophages were labelled with Fuse-it-Color Red membrane dye (Ibidi, UK) 
according to manufacturer’s instructions and excited using a 561 nm laser. Apoptotic 
neutrophils were labelled with 1μg/ml pHrodo Green STP Ester for 30 mins at RT. 
The pHrodo fluorescence was excited with a 488 nm laser. Fuse-it Color fluorescence 
was excited with a 561 nm laser. The camera EM gain and exposure time were kept 
the same throughout the imaging. The imaging was performed in a heated chamber 
that was maintained at 37 ºC +5% CO2. A time-series was performed in 3 fields of 
view (FOV) with 15 frames taken at 3 min intervals (45 mins total). For each 
timeframe a Z stack of 95 optical planes over 32 μm was taken.  
 
2.5 Cell Line Culture 
 
A549 (pulmonary adenocarcinoma cell line, ATCC, CCL185) cells and Chinese 
Hamster Ovary (epithelial-like cell line) cells were provided by Brian Mchugh 
(University of Edinburgh) were cultured in DMEM, +10% fetal bovine serum (FBS), 
+2mM L-glutamine, +1% Penicillin/Streptomycin, in T75 tissue culture flasks or 8 well 
Lab-Tek II Confocal Chambers. Cell proliferation was monitored using an inverted 
light microscope until the population was ~75% confluent. At confluency, cells were 
washed with pre-warmed DPBS and detached using 2ml of Trypsin- EDTA at 37 ºC 
for 5 min. The detached cells were either diluted into fresh culture media in a T75 




2.6 MR-Nanobody Characterisation  
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2.6.1 Probe synthesis 
 
MMR-Nanobody synthesis was performed by Gavin Birch (Bradley Group, University 
of Edinburgh) as a collaborator on this project. The nanobody structure was 
originally obtained from Vrije Universiteit Brussel, in collaboration with Edinburgh 
Molecular Imaging. The protein sequence was published in the European patent 
EP2855526B1. The following fluorophore conjugation method has been provided 
and used with permission by Gavin Birch: Fluorophore labelling of this protein was 
carried out through mild conditions with the N-hydroxysuccinimidyl (NHS) ester 
reactive dye which, upon reaction with a lysine, would form an amide bond between 
the protein and fluorophore. The fluorophore used was a sulfonated Cy5 dye. To 
purify the labelled protein from residual dye both PD-10 gel filtration and spin 
centrifugation (Amicon spin concentrators) were used. 
 
2.6.2 Stock concentrations and spectral reads 
 
The stock concentration of the probe was validated using a fluorescent 
spectrophotometer exciting at 630 nm. Concentration was interpolated from 
fluorescent intensity from a standard curve of known sulphonated Cyanine 5 dye 
concentrations.  
 
2.6.3 Confocal imaging for cell-type specificity  
 
Peripheral blood monocytes were isolated as described in section 2.3.2 and adhered 
to wells of Lab-Tek II Confocal Chambers for 45 min in IMDM media. MDMs were 
cultured on the surface of the confocal chambers as described in section 2.3.3. 
Human polymorphonuclear cells were isolated as described in section 2.3.1 and 
adhered to the bottom of Lab-Tek II Confocal Chambers that had been previously 
coated with Fibronectin to aid adherence. A549 cells were cultured on the confocal 
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chambers as described in section 2.5. Between 100,000 and 200,000 cells were used 
per well. Monocytes and MDMs were counterstained with 1 µM of Cell Tracker Green 
CMFDA dye for 10 min at 37 ºC then washed with fresh IMDM. The MMR-nanobody 
was diluted to 50 nM final concentration in IMDM media (+5% autologous serum) 
and 500 µl was added per well. The MMR-nanobody was incubated with cells for 20 
min before being analysed using a confocal laser-scanning microscope (CLSM). 
CLSM systems used for this assay were Leica Sp5 and Leica Sp8, using 40x oil or 63x 
oil immersion lens. A 488 nm Argon laser and emitted light detected with meta 
detector (500-530nm) was used to excite Cell Tracker Green if used in the assay. For 
MMR-Nanobody excitation, a 633 nm HeNe laser was used and emitted light 
detected with meta detector (660-750nm). with a pixel dwell time of 4 μs with a 
pinhole diameter corresponding to 1 Airy unit. Fields of view were chosen using Cell 
Tracker Green channel or brightfield.  
 
2.6.4 Flow cytometric analysis of cell-type specificity  
 
Monocytes and MDMs were adhered to the bottom of 48 well tissue culture plates. 
The cell media was aspirated and replaced with 500 µl of IMDM (+5% autologous 
serum) with 50 nM of MMR-nanobody and incubated at 37 ºC for 20 min. The 
nanobody-containing media was aspirated, and cells were detached using Trypsin- 
EDTA at 37 ºC for 5 min before being analysed using a BD FACS Calibur or Attune 
NxT flow cytometer. During flow cytometric analysis, voltages remained constant 
throughout the experiment and data was collected on a logarithmic scale, collecting 
5,000 events. Samples were run in duplicate. Post-experiment analysis was 
performed using FlowJo version 10.6. FSC/SSC characteristics were used to gate on 
cells and eliminate debris. The MMR-nanobody signal was excited using the FL4 
channel of a BD FACS Calibur or the RL1 channel of Attune NxT flow cytometer. For 
quantification, the geometric mean of the MMR-nanobody signal was used, with 
data presented as mean fluorescent units (MFU) from independent experiments.  
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2.6.5 Labelling bronchoalveolar lavage cells 
 
Bronchoalveolar lavage cells were isolated by first passing through a 70 µm cell 
strainer to exclude large debris. The cell population was centrifuged at 300 g for 5 
min to pellet cells, and subsequently resuspended in IMDM. The cells were counted 
using a Nucleocounter and a cytospin was used to determine cell morphology. Cells 
were adhered to 8 well LabTek Confocal chambers for 1 hr at 37 ºC, at 100,000 cells 
per well. Following adherence the media was aspirated and replaced with IMDM 
(+5% human AB serum) with 50 nM MMR-nanobody and left to incubate at 37 ºC for 
20 min. Confocal imaging was carried out as described in section 2.6.3. 
 
2.6.6 Mannan blocking 
 
Dry Mannan from Saccharomyces cerevisiae was acquired from Sigma Aldrich and 
solubilised in PBS. Solubilised mannan was used at a final concentration of 2 mg/ml 
together with 50 nM of MMR-nanobody when labelling MDMs. The effect of mannan 
was assessed using flow cytometric analysis as described in section 2.6.4.  
 
2.6.7 Transfection of MRC1 into CHO cells 
 
Adherent CHO cells were grown on 6 well tissue culture flasks in DMEM without 
antibiotics until 90% confluent. An MRC1 expression plasmid coding for a human 
mannose receptor was obtained from Origene (Germany, SC303200), using a 
pCMV6 tag-free Entry vector. The dry plasmid was solubilised in 100 µl of sterile H20. 
50 µl of plasmid DNA solution was diluted in 50 µl of Opti-MEM reduced Serum 
Medium (Thermofisher, 31985062) and gently mixed. 2 µl of Lipofectamine 3000 
(Thermofisher) was diluted in 50 µl od Opti-MEM medium and mixed gently, before 
incubated at RT for 5 min. The DNA and Lipofectamine mixtures were combined and 
incubated at RT for 20 min. 100 µl of Lipofectamine-plasmid mixture was added to 
individual wells of confluent cells. A lipofectamine-only control was added to 
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separate wells. The plate was incubated for 48 hr at 37 ºC 5% CO2 before being 
assessed for transgene expression using flow cytometry. Flow cytometric analysis 
followed the same protocol described in sections 2.3.5 and 2.6.4, using a PE anti-
CD206 mAb and an isotype control to determine mannose receptor expression, and 
50 nM of MR-Nanobody to determine labelling. 
 
2.6.8 Spinning-disc confocal microscopy of probe localisation and labelling 
kinetics 
 
MDMs were cultured on wells of an 8 well LabTek confocal chamber. For probe 
localisation assays, the cells were labelled with 1 µM of Cell Tracker Green CMFDA 
for 10 min at 37 ºC +5% CO2. The media was aspirated and replaced with IMDM (+5% 
autologous serum) with a final concentration of 50 nM MMR-Nanobody. The cells 
were incubated for 20 min at 37 ºC +5% CO2 before being analysed on an SDCM. Cell 
Tracker Green fluorescence was excited with a 488 nm laser, while MMR-nanobody 
fluorescence was excited with a 640 nm laser. The camera EM gain and exposure 
times were kept the same for each channel throughout imaging.  For each image a 
Z stack of 135 optical planes over 31 μm was taken. For imaging kinetics assays, the 
same labelling steps applied, though prior to imaging, the MDM media was 
aspirated and replaced with 25 µl fresh IMDM to cover the surface of the well and 
taken to SDCM for imaging. A time-series was taken at 30 sec intervals for 15 min. 
Following the first timeframe, 500 µl of 50 nM MMR-nanobody was added to the well 
as subsequent timeframes captured the labelling kinetics.  
 
 
2.6.9 Image analysis of spinning-disc confocal data 
 
Using the green 488 nm channel on Imaris (Bitplane, Switzerland) image analysis 
programme, a region of interest (ROI) was drawn in a 3D space around an individual 
macrophage labelled with Cell Tracker Green. A 3D isosurface was created from the 
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green signal within the ROI (surface detail of 2µm, thresholding on absolute 
intensity to cover the entire cell). Touching objects (cells, debris) were split using the 
region growing tool (seed point diameter 12 µm) and seed points manually classified 
as the centre of the macrophage in the ROI. An isosurface was generated from this 
seed point based on a voxel number threshold that recognised the whole 
macrophage cell surface. This semi-automated algorithm was subsequently applied 
to the whole FOV to create isosurface of all cells. Cells touching the edge of the FOV 
were eliminated from analysis. The intensity mean of the 640 nm (MR-nanobody 
signal) channel was quantified in each isosurface (macrophage cell mask).  
 
2.7 Optical Endomicroscopy of Macrophage Phagocytosis 
 
2.7.1 Phagocytosis imaging assay using a widefield OEM system  
 
MDMs were cultured on wells of polystyrene 48 well tissue culture plates. They were 
labelled with 1 µM Syto 82 far-red nucleic acid stain for 10 min at 37 ºC +5% CO2.  
Apoptotic neutrophils were labelled with 1 µg/ml of pHrodo Green STP Ester for 30 
min at RT before being pelleted and resuspended in IMDM +5% autologous serum. 
MDM media was aspirated and replaced with apoptotic neutrophils at a ratio of six 
neutrophils per macrophage in each well (each well contained 300,000 macrophages 
and 1,800,000 neutrophils). This co-culture was incubated for 45 min at 37 ºC +5% 
CO2 before imaging with a widefield OEM system. The imaging system comprised 
of three LED excitation sources, as described previously 130. A 470 nm LED was used 
to excite pHrodo Green fluorescence. A 625 nm LED was used to excite Syto 82 
fluorescence. Images were captured with a 25 ms exposure time. An Alveoflex 
(Mauna Kea Technologies) commercial imaging fibre bundle was used to direct 
excited light onto the tissue culture plate. The imaging fibre had a zero working 
distance, meaning the fibre had to be physically touching the cell culture to perform 
imaging. Emitted light from the tissue culture plates returned back up the imaging 
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fibre and detecting using a monochromatic camera connected to a computer. 
Recordings of the tissue culture plate in real time was 10 frames per second.  
 
2.7.2 Emission spectroscopy of primary human alveolar macrophages and lung 
tissue 
 
A commercial spectrometer (VIS-NIR-ES, Ocean Optics) was coupled to an Alveoflex 
imaging fibre. Primary human alveolar macrophages were isolated from 
bronchoalveolar lavage samples as described in section 2.6.5. Human lung tissue 
was acquired from the Edinburgh BioResource. Isolated AMs and lung tissue were 
adhered to tissue culture plates and the spectra captured by touching the imaging 
fibre against the well (for adhered cells) or directly onto lung tissue.  
 
2.7.3 Spectral Ratio Imaging system setup  
 
The SR imaging system described in this thesis was built by Helen Parker, University 
of Edinburgh, who collaborated on this work by supplying the system and helping 
with imaging acquisition of samples. The following is a description of the SR system 
which has been adapted with permission from Helen Parker and has been previously 
published 147.  
 
 
A 470 nm LED excitation source was directed through a standard epi-fluorescence 
arrangement of excitation filter and dichroic (FITC-Ex01-Clin-25, Semrock). The 
excitation light was then coupled to a bespoke fibre imaging bundle described 
previously 148. The emitted fluorescence from the target propagated through the 
fibre and, after passing through the epi-fluorescence dichroic and emission filter, 
was split into two optical paths according to a cut-off wavelength defined by the 
dichroic mirror. An optical chopper was installed into the long wavelength path. The 
two paths were recombined using another dichroic mirror and focused onto a 
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monochromatic CMOS camera (GS3-U3-23S6M-C Grasshopper, Point Grey, 
Canada). A PC operated a triggering unit to synchronise the chopper rotation with 
camera acquisition. This ensured that the sequential full wavelength and short 
wavelength images were taken at 50 ms exposure time. From this, we derived a 
short wavelength channel (< 605 nm) and a long wavelength channel (> 605 nm) 
whilst acquiring images at 10 fps video rate. 
 
2.7.4 Spectral Ratio phagocytosis imaging  
 
MDMs were cultured on the wells of 48 well tissue culture plates. In assays where the 
MDMs were labelled, 1 µM of Syto 81 Orange nucleic acid stain was used to label the 
cells for 20 min at 37 ºC +5% CO2. Targets used for the SR assays were either 
apoptotic neutrophils, labelled with pHrodo Green STP as described in section 2.4.6, 
or pHrodo Green E. Coli Bioparticles, prepared as described in section 2.4.2. 
Macrophages were co-cultured with a target population for 45 min at 37º C +5% CO2. 
Following incubation the co-culture plate was imaged using the SR system coupled 
to a bespoke imaging fibre bundle described in section 2.7.3 and published 





2.8 Statistical analysis 
 
All experiments were performed twice or three times and is outlined in figure 
legends. Paired data columns (from crlls of the same culture) were evaluated using 
a paired Student’s t test with GraphPad Prism version 8.00 for Mac OS (GraphPad 








































 Chapter Three: Characterising an in vitro 
















The study of macrophage phenotype – such as the receptors they express, cytokines 
they produce and their morphology - is an important avenue to improving our 
understanding of how tissues maintain inflammatory homeostasis 149. Macrophages 
play an integral role in maintaining this homeostasis: whether mounting an 
inflammatory response to invading pathogens or switching activity to resolve an 
immune response that is no longer required 150,151. If this niche role for macrophages 
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to orchestrate inflammatory homeostasis becomes perturbed, the consequence is 
often the manifestation of a range of inflammatory diseases 152,75.  
 
In order to improve our knowledge of how macrophages carry out their functions of 
orchestrating inflammatory responses, model systems are required to interrogate 
macrophages in detail 153,154. This is due limited avenues available to profile these 
cells in situ. Systems capable of capturing dynamic cell functions such as 
phagocytosis inside the human body have not yet been established. Model systems 
can be used to observe the plasticity of macrophage phenotype in different 
inflammatory environments - including their receptor expression and downstream 
signalling - to how they specifically interact with phagocytic targets 154. Model 
systems used for these purposes have been developed to carry out this interrogation 
in a controlled, in vitro setting. These have taken the form of immortal cell lines from 
the monocyte lineage, such as THP-1 cells, U937, and RAW cells 155,156,157. These cell 
lines allow for rapid expansion of readily available monocyte-like populations that 
can be differentiated under defined experimental conditions into macrophages. An 
alternative in vitro model is of isolating peripheral blood monocytes from whole 
blood and culturing them in vitro in the presence of serum and other stimulants to 
differentiate and adopt a mature macrophage phenotype 158. Each approach can 
have advantages and drawbacks over the other. While freshly isolated monocyte 
differentiation may offer a more biologically relevant macrophage model, there can 
be ethical and logistical barriers to consistently use this approach 154. Working with 
healthy human cells requires the setup of a blood retrieval resources that allows for 
collection of samples that is ethically regulated. Freshly isolated human cells also 
have a limited lifespan that requires multiple donations for repeated experiments. 
Cells lines are more readily available, with a more homogenous genetic background 
159. However, this genetic homogeneity may yield results that are less biologically 
relevant or difficult to replicate in more complex biological systems. There is a 
growing evidence base behind how any given macrophage population can be highly 
heterogenous, therefore the effects of potential therapies that target macrophages 
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in disease could generate inconclusive results depending on how representative a 
model population is 160,55. Indeed, previous work has shown functional differences 
between cell line models and MDM models, such as phagocytic activity 154. If these 
functions are relevant to the area of macrophage biology in a particular study, then 
choice of model becomes an important factor.  
 
Ascertaining which cell-surface receptors are present on macrophages under 
specific conditions carry therapeutic and diagnostic applications. Characterising 
these markers can aid in targeting macrophages, either for pharmaceutical delivery 
or simply to aid in potential approaches in experimental medicine to profile 
macrophages  161,22. Often these markers are cell-surface receptors, for which 
targeting ligands can be generated. However, the receptor expression phenotype on 
model cell lines, such as THP-1, can differ significantly from blood-derived 
macrophages, which may skew the conclusions made about the relationship 
between certain receptors and a cell phenotype 162. The expression profile of a given 
receptor could also vary significantly between in vivo macrophage populations 
something that is difficult to replicate in some models 163.  
 
In addition to the establishment of in vitro systems to study macrophage biology, 
assays also need to be in place to interrogate their phenotype (receptor expression, 
cytokine production) and how they perform certain activities such as phagocytosis. 
The process of macrophage phagocytosis is typically examined using in vitro 
methodology 164,165. It is also possible that primary macrophages can be acquired 
directly from tissue (or from a broncho-alveolar lavage in the case of acquiring 
alveolar macrophages for ex vivo experiments) 166. Phagocytic targets can be 
cultured bacteria (live, fixed, or killed), human cells and immortal cell lines induced 
to undergo apoptosis, or inert non-physiological particles 167. The targets are often 
labelled in some way to track their internalisation into a macrophage. Following 
incubation with labelled targets, macrophages that acquire the target’s label can be 
identified using optical systems such as flow cytometry or imaged with microscopy 
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to confirm internalisation 168,169. The use of flow cytometry in this context can 
provide accurate quantification of phagocytosis by macrophages on a single-cell 
basis.  
 
Macrophages can serve as therapeutic targets to alter their function and rebalance 
immune systems homeostasis. Efforts to modulate macrophage receptor 
expression, cytokine production and phagocytic activity have been established 
through in vitro methodology, which opens up further avenues to modulate their 
phenotype in vivo in a disease setting  160,55. A common example of pharmacological 
manipulation of macrophages to promote the resolution of inflammation is the use 
of synthetic glucocorticoids, which can be potent anti-inflammatory agents, down-
regulating a number of inflammatory processes (such as a reduction in IL-1, IL-6 and 
TNF, and IFN production) in macrophages and instead promoting resolution 
mechanisms such as clearance of apoptotic material 170,171.  
 
In vitro assay systems have also been used to confirm the phagocytic dysfunction of 
macrophages in disease states that are associated with poor pathogen clearance. 
For example, AMs acquired from patients with COPD have shown reduced capacity 
to phagocytose apoptotic human cells and different strains of bacteria associated 
with COPD 77,76. As restoring phagocytic function to AMs may reduce exacerbations 
in COPD, these in vitro assays have been used to assess the restorative effects of 
compounds on AM phagocytosis. One example is sulforaphane: a naturally occurring 
compound extracted from broccoli 172. Sulforaphane is an agonist for the 
transcription factor Nrf2, promoting anti-oxidant gene transcription and ultimately 
a microbicidal phenotype 173,100. Pre-clinical use of sulforaphane has shown to 
improve the bacterial clearance by AMs of COPD patient macrophages 100.  
 
The aims of the following chapter were to: 
 
 63
• Set up an in vitro cell culture model of differentiating human peripheral blood 
monocytes into macrophages 
• Use the monocyte-derived macrophages to establish assays profiling the 
phagocytic activity of macrophages with different biologically relevant targets, as 




3.2 An in vitro Model of Human Monocyte-Derived 
Macrophages 
 
As the overarching goal of this thesis was to explore novel approaches to profiling 
macrophages, a suitable in vitro cell model was required to carry out my 
investigations into macrophage phenotype and activity. I identified blood-derived 
monocytes differentiated into macrophages as the most suitable, as I anticipated 
they would closer reflect how macrophages would present in vitro. Peripheral blood 
mononuclear cells (PBMC) were isolated from the whole blood of healthy human 
volunteers. The flow scatter plot shown in Figure 3.1B shows that the scatter 
characteristics (which provide broad information on the size and granularity of cells) 
of the PBMC layer represent the majority being lymphocytes, with fewer than 20% 
being monocytes. In order to further enrich the monocyte population, I used an 
immunomagnetic cell separation procedure employing negative selection.  A 
biotinylated antibody cocktail was used to label all non-monocytes present in the 
PBMC population, followed by binding of anti-biotin-labelled magnetic microbeads. 
The cells were passed through a magnetic separation column to negatively select for 
monocytes. Figure 3.1D shows that, following this magnetic separation, the purity 
of the monocyte population was greater than 80%, with a small minority of 
lymphocytes remaining. An accompanying cell cytospin shown in Figure 3.1C 
showed the morphology of the of cells following magnetic separation are 
representative of monocytes, based on a typical cell diameter of over 15 µm and a 




chosen in order to distinguish monocytes and macrophages. The rationale behind 
the choice for each mAb is outlined in Table 3.1. Flow cytometric analysis of the 
expression pattern of the different cell-surface receptors showed that that common 
markers for monocytes and macrophages, such as CD11b and HLA-DR, were 
expressed on freshly isolated monocytes and monocytes cultured for 6 days in vitro 
(Figure 3.2A). However, cells post-culture showed significantly higher expression of 
more macrophage-specific markers, such as CD80, CD163, and CD206 (Figure 3.2C). 
This data suggests that the monocyte-derived macrophages (MDM) represented a 




Table 3.1 Receptor expression panel for validating monocyte differentiation into mature macrophages. The table 
outlines each receptor in the panel and its associated function. The expression of the receptor across monocytes 












3.3 Characterising the phagocytic activity of MDM with 
biologically relevant targets 
 
3.3.1 Polystyrene microspheres as a phagocytic target causes issues with false-
positive phagocytic signal and poor validation with a negative control 
 
The phagocytic capacity of the MDMs was characterised using a flow cytometric-
based assay described and characterised in previous studies 164,168. The assay first 
used 1 µm polystyrene microspheres labelled with carboxyfluorescein (FAM) as a 
target. Microspheres can represent inert particles that macrophages are required to 
clear, particularly alveolar macrophages which encounter inhaled particulates in the 
lung 177. To profile phagocytosis, the MDMs were first incubated with different 
concentrations of microspheres for a 45 min period before being analysed on a flow 
cytometer. When analysed, the amount of FAM signal from the microspheres in the 
gated macrophage population was used as a quantifiable measure of phagocytosis. 
Figure 3.4 shows different microsphere to macrophage ratios and the phagocytic 
signal shown from each. For each ratio there is a clear subset of macrophages 
negative for the microsphere fluorescence that can be indicative of non-phagocytic 
cells. Increasing the microsphere to cell ratio increases the target signal in the 
macrophage population following the 45 min incubation. Figure 3.4 also shows the 
amount of microsphere signal in the gated macrophages at 0 min, when no contact 
time between cell and target had been allowed to take place. This shows the amount 
of ‘coincidence’ signal generated for each microsphere to macrophage ratio when 
analysed by flow cytometry. Any microsphere positive signal at this time point is 
assumed to represent a false-positive for phagocytosis. This coincidence effect 













Figure 3.8 The effect of Cytochalasin D as a negative control for imaging macrophage phagocytosis of bacteria. 
Monocyte-derived macrophages were incubated with E. Coli labelled with 20 µg/ml pHrodo Green for 45 min. 
Cytochalasin D was used as a negative control to prevent phagocytosis. Images following incubation were taken 
with a CLSM. Images are representative of two independent experiments.  
 
Another biologically relevant target used to profile macrophage phagocytosis was 
human apoptotic neutrophils, to be used as a relevant target for efferocytosis, a 
distinct mechanism of internalisation used by macrophages. Human blood 
neutrophils were cultured for 20 hr to induce apoptosis. While not producing a 
completely homogenous apoptotic population, this method has been previously 
used to induce <50% apoptosis in a neutrophil population 171. The apoptotic 
neutrophils were then labelled with chloromethyl fluorescein diacetate (CMFDA) 
cell dye and incubated with mature MDMs at a ratio of 6 neutrophils to one 
macrophage, following previously established methodology 168. After co-incubation 
with apoptotic targets, macrophages (and bound apoptotic cells) were detached 
with trypsin/EDTA for 5 min at 37 ºC and then analysed by flow cytometry. Two 
distinct populations of macrophages could be distinguished in terms of levels of 
fluorescence (Figure 3.9). These corresponded to CMFDA-negative (non-
phagocytic) and a CMFDA-positive (phagocytic) MDMs, respectively. Importantly, 





snapshots show an image cropped to a representative macrophage, which is labelled 
with a red membrane stain. Over time, there is emergence of pHrodo green signal, 
indicative of the macrophage having internalised a neutrophil and pHrodo 




Figure 3.11 Optimising the real-time imaging of macrophage. A 45 min time-series was taken using a SDCM. The 
snapshots show an image cropped to a macrophage labelled with fuse-it color Red membrane stain incubated 
with apoptotic neutrophils labelled with pHrodo Green STP ester. The snapshots show the development of 
pHrodo signal around the macrophage over time. Snapshots of the time-lapse are representative of two 
independent experiments.  
 
3.3.3 Using flow cytometry to investigate the effect of pharmaceutical 






Having established assays for quantification of macrophage phagocytosis, I next 
examined the use of pharmaceutical modulators to macrophage activity. This was 
to confirm that this in vitro assay can effectively quantify the changes to macrophage 
activity. The glucocorticoid dexamethasone (Dex) was first used to augment 
efferocytosis in MDMs. Dex is well established as a modulator of macrophage 
phenotype, driving them to a more pro-resolving state, which includes an increased 
capacity to clear apoptotic cells 164. Freshly isolated monocytes were treated with 
Dex from day 0 of their in vitro culture into macrophages. Figure 3.12A shows that, 
following culture with Dex, the morphology of the MDMs are distinguishable from 
an untreated population. The Dex-treated cells are smaller in size with a more 
homogenous, rounded shape (Figure 3.12A). This morphology is a well-defined 
characteristic appearance of Dex-induced MDM differentiation. The efferocytosis 
assay outlined in Figure 3.9 was then repeated with the Dex-treated cells. Dex 
significantly increased internalisation of apoptotic neutrophils by the Dex-treated 





Figure 3.12 Quantifying the effect of dexamethasone on monocyte-derived macrophage efferocytosis. 
Peripheral blood monocytes were differentiated into macrophages over a 6 day culture, +/- 500 nM 
dexamethasone from day 0. A) The comparison in morphology of untreated and Dex-treated macrophages, 
using brightfield images taken with an EVOS fluorescent microscope. B) Flow cytometric analysis of 
efferocytosis of apoptotic neutrophils, labelled with CMFDA, by macrophages in different Dex treatment 
conditions. Graph shows the quantification of efferocytosis as the percentage of gated MDM events that were 
CMFDA+, +/- Dexamethasone ±SEM n=5. Comparison between groups performed with paired t test. ***= 
P≤0.001  
 
The effect of another known modulator of phagocytic activity, Sulforaphane, was 
also assessed. Sulforaphane is a compound that acts as an agonist for the 
transcription factor Nrf2 101. The stimulation of Nrf2 has shown to be instrumental in 
the microbicidal processes that occur in macrophages 100. Mature human MDMs 
were treated with sulforaphane for 18 hr prior to performing the same phagocytosis 
assay shown in Figure 3.7. There was no significant effect by sulforaphane to 
modulate the macrophage response to clearing E. coli bacteria (Figure 3.13). This 
suggests that, at least for healthy in vitro MDMs, the augmenting effect of 
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The results presented in this chapter outline studies to optically profile macrophage 
phagocytic activity. An in vitro cell culture model of human monocyte differentiation 
into macrophages was characterised. These MDMs were used to establish and 
further characterise assays to profile phagocytic activity. Using a flow cytometry 
assay to quantify phagocytosis was successful and could be applied to different 
biological targets and monitor the effects of pharmacological manipulation of 
macrophage activity.  
 
3.4.1 The human monocyte-derived macrophage model 
 
The choice of using human MDMs for further in vitro analysis in this work was to 
maintain biological relevance to primary human macrophages, in the expectation 
that the workflow in future chapters would involve profiling macrophages obtained 
from human patients with COPD. The importance of choosing this model was to 
work with MDMs from multiple donors that would not be genetically homogenous, 
as would be the case with a cell line 159. While this inevitably introduces some 
variability in experimental results, for example seen as donor variability in how 
isolated monocytes respond to in vitro differentiation – this method would closer 
reflect differences in primary human macrophages present in patients’ lungs in situ 
180. To reduce the amount of variability between independent cultures, each 
monocyte population was enriched by a negative selection technique to reduce the 
number of lymphocytes present. Lymphocytes produce cytokines (IFN, TNF, IL-1, IL-
4 IL-10, IL-13) when in culture with monocytes that can dictate the activation state 
of mature macrophages 181. The alternative would be to repeatedly wash 
lymphocytes away from the adhered monocyte in culture, risking disturbing and 
detaching a proportion of monocytes. The selection process did remove the vast 
majority of lymphocytes, which removed the need for washes which resulted in 
more intact macrophage monolayers at the end of each culture.  
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Analysis of the cell surface receptor profile for MDM revealed expression of 
macrophage-specific markers such as: CD80, CD163, and CD206 182, although there 
was a degree of variability in expression of some receptors. This became more 
apparent when quantifying the effects of known polarising agents: IFN , LPS, and 
interleukin-4. Pro-inflammatory stimulants (IFN and LPS) were found to significantly 
increase CD80 expression when compared to a non-stimulated MDM control. 
However, in some cultures, CD80 expression was just as high in the “unstimulated” 
condition following some cultures, epitomising the variability in differentiation of 
MDMs during in vitro culture. It is possible that the levels of other cytokines that may 
have been present in the autologous serum would influence the activation of mature 
macrophages to a particular phenotype, without further stimulation 183. 
Furthermore, the presence of lymphocytes could also influence the differentiation 
of monocytes in culture and the ultimate expression of cell-surface receptors 184. As 
mentioned, steps had already been taken to reduce the impact of lymphocyte 
presence in the culture media. Inter-experimental variability between MDM 
cultures, might be reduced by use of commercially available human AB serum or 
serum-free media which have shown successful monocyte-macrophage 
differentiation 185.  
 
3.4.2 A flow-cytometric assay to characterise macrophage phagocytosis of 
different targets 
 
The use of flow cytometry to quantify uptake of fluorescent targets by macrophages 
has long been established. The experiments presented in this chapter identified 
relevant targets for optimal quantification of MDM phagocytosis. These assays were 




The use of polystyrene microspheres proved the most challenging target to model 
the interaction between primary alveolar macrophages and potentially relevant 
targets 186,77. In flow cytometric analysis, it became apparent that when MDM and 
microsphere targets were mixed and analysed immediately there was a positive 
“coincidence” signal detectable. There are two possible reasons for this coincidence 
effect: the size and charge of the microspheres. The polystyrene microspheres used 
were 1 µm in size, smaller than the other targets used in this chapter. Their small size 
and high macrophage to target ratio may have resulted in particles passing through 
the flow cell alongside a macrophage. In addition, the charge of the microspheres 
may have led to rapid binding to the surface of macrophages non-specifically 187. This 
may explain the lack of effect of Cytochalasin D , which may prevent phagocytosis, 
but not binding via blocking actin polymerisation 178. Others have studied the 
downstream effect of measuring macrophage phagocytosis with differently sized 
and charged microspheres 188. It revealed the importance of considering these 
factors when using an inert particle as a target for phagocytic assays. For example, 
they showed that a size of 1 µm was ideal for alveolar microspheres to internalise, 
though this also required added functional groups (amine or carboxyl) to the 
microsphere to elicit phagocytosis 188.  
 
In addition to polystyrene microspheres, fluorescently labelled E. coli were used as a 
target to quantify bacterial phagocytosis using a flow cytometric assay. The use of 
E. coli was considered one relevant bacterial target for modelling alveolar 
macrophage interactions with pathogens in lung disease. Previous studies have 
outlined that defective AMs in COPD show reduced phagocytosis of E. coli  76. 
However, one of the most common pathogens associated with defective 
macrophage phagocytosis and recurring infection in COPD, is Streptococcus 
pneumoniae 189. Therefore, for future development of this assay, it would be 
worthwhile to explore labelling of other bacterial species to quantify phagocytosis in 
different macrophage populations.   
 
 83
Measuring phagocytosis of apoptotic neutrophils (efferocytosis) is important as the 
clearance of apoptotic material is essential to the resolution of inflammation and 
maintaining tissue homeostasis 190. Failure to clear apoptotic cells effectively would 
lead to an accumulation of necrotic material that would ultimately exacerbate 
inflammation 191. In this chapter, I demonstrated the use of CMFDA- and pHrodo-
labelled apoptotic neutrophils for quantifying macrophage efferocytosis 168. 
 
3.4.3 Manipulating the phagocytic activity of macrophages  
 
Importantly, I was able to demonstrate a quantifiable effect of treatments to 
modulate MDM phagocytosis. For example, one of the anti-inflammatory effect of 
Dex and other synthetic glucocorticoids on macrophages is to promote efferocytosis 
164,171. Dex treatment induced a morphologically homogenous MDM population with 
a distinct rounded shape, also reported by others 171. This assay could be used to 
investigate the effect that Dex has on primary human alveolar macrophages in a 
diseased state. Defective apoptotic cell clearance exacerbates the pathology of 
COPD, contributing to the viscous cycle of lung function decline 88. Therefore, 
identifying therapeutic strategies to improve apoptotic cell clearance in COPD 
would be hugely beneficial. Synthetic glucocorticoids like Dex have long been used 
for their anti-inflammatory properties in inflammatory lung disease. Only one study 
to date reported limited improvement by Dex on efferocytosis by COPD AMs 192. 
Isolating AMs from COPD patients and quantifying the effect dexamethasone has 
on efferocytosis would shed some more light on this, such as elucidating the 
underlying mechanisms regulating efferocytosis that become defective. Some 
studies have shown that the use of macrolide antibiotics, particularly azithromycin, 
do improve efferocytosis by COPD AMs in vitro 193. This effect was also 
complemented by a reduction in recurring infections in COPD patients following 
macrolide treatment. This offers an alternative pharmaceutical approach to apply to 
the characterisation of augmenting macrophage efferocytosis. It may also offer a 
potential route to work synergistically with glucocorticoids such as Dex.  
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The compound sulforaphane was tested for its ability to augment bacterial 
phagocytosis by MDMs. However, sulforaphane treatment did not increase bacterial 
internalisation by MDMs in these experiments. Previous studies have shown that 
sulforaphane was successfully used to improve bacterial clearance by AMs from 
COPD patients 100. However, this could be likened to rescuing impaired activity, 
rather than augmenting phagocytic capacity in otherwise healthy macrophages, 
which is supported in the same study, which found that sulforaphane had no effect 
on healthy control macrophages 100. Sulforaphane has been shown to augment 
phagocytosis in other in vitro macrophage models,  however this was using RAW 
cells as a macrophage model and 2 µm polystyrene beads as phagocytic targets 173. 
Besides, the effect sulforaphane had was more pronounced in the absence or lower 
amounts of serum. This suggests sulforaphane acts to improve phagocytosis of non-
opsonised targets Future work from this chapter should explore the effect 
sulforaphane has on the phagocytosis by human MDMs of bacteria following 
opsonisation with serum proteins or not.  
 
3.4.4 Limitations and conclusions from this chapter 
 
The work in this chapter establishes an in vitro monocyte-derived macrophage 
model for subsequent studies in this thesis, together with assays to quantify the 
phagocytic activity of macrophages, as well as their response to pharmacological 
agents. These studies form the foundation for development of more novel 
approaches to profiling phagocytic activity in future chapters.  
 
However, there are some limitations to the work in this chapter. Only the human 
MDM were profiled in this chapter, which will likely differ in phenotype to primary 
human alveolar macrophages. It would be important to assess phagocytosis of 
different targets by primary AMs, as well as investigating how they respond to 
pharmacological manipulation. Although I did not establish an assay for quantitation 
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of phagocytosis of 1 µM polystyrene microspheres it would be interesting to explore 
the most appropriate size, charge, and opsonisation state of microsphere would be 
most effective for quantification of phagocytosis. The time-lapse imaging of 
neutrophil efferocytosis could also have been extended to use image analysis tools 
to study the kinetics of macrophage internalisation processes in detail. This system 
could have been used to further study the impact of pharmacological treatments to 
manipulate MDM phenotype (e.g. Dex) upon phagocytic activity.  
 
In conclusion, this chapter successfully established the starting point for optically 
profiling macrophages. The following chapters develop these methods of profiling 
macrophages, by their phenotype and phagocytic activity, using alternative 
methods that carry the potential to perform this interrogation of primary human 






























 Chapter Four: A Fluorescent Nanobody for 

















The mannose receptor (MR) is an endocytic receptor with a broad binding specificity 
that spans both endogenous and foreign material 194. It is a member of the C-type 
lectin family of receptors and was first recognised from its activity in clearing 
endogenous glycoproteins by alveolar macrophages 195,196. Targets for the receptor 
also include sugars present on the surface of microorganisms which are not present 
on mammalian cells, such as mannose, fucose, and N-acetylglucosamine 197.  
 
When the MR binds to its targets, internalisation occurs in a clatherin-dependent 
manner 198. The receptor requires actin polymerisation in order to recycle to and 
from the cell membrane when shuttling targets from the surface of the cell to the 
endocytic compartments 194. This has been determined by downregulating 
expression of the MR in the presence of cytochalasin D, an inhibitor of actin 
polymerisation 199. Once  transported inside the cell, acidification in the early 
endosome is the likely trigger for the MR to dissociate from its target and return to 
the cell surface 194. Work to quantify the relative expression of the MR throughout 
the cell has shown the majority is present in early endosomal compartments 198. 
What’s more, MR recycling activity occurs even without the presence of ligands to 
the receptor 198.  
 
A lack of signalling motifs on the cytoplasmic portion of the MR support a hypothesis 
that the receptor does not directly lead to microbicidal immune cell activation 200. If 
the MR is involved in triggering signalling cascades following ligand binding, it would 
likely require involvement from other receptors. This points to a unique role the 
receptor plays in clearing microorganisms and debris while preserving inflammatory 
homeostasis in the microenvironment.  
 
A number of tissue resident macrophages, including alveolar macrophages, are 
known to highly express the MR 201. Monocyte-derived macrophages cultured in vitro 
also have a high expression of the MR, while non-differentiated monocytes are 
negative 202. Further in vitro work has shown that expression of the MR is associated 
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with polarised states of macrophages. While pro-resolving stimuli, such as IL-10, IL-
4 and some corticosteroids increase MR expression, pro-inflammatory stimuli such 
as interferon-gamma and LPS have a negative effect 196. This observation suggests 
that modulation of expression is key to the role of the MR in both innate and 
adaptive immunity. Evidence of down-regulation by pro-inflammatory stimuli, 
together with evidence of MR activity increasing antigen uptake and T cell 
presentation, appears to endow the receptor with a niche role in driving local 
macrophage activity away from inflammation and instead to promoting a more 
adaptive immune response to microbes 203.  
 
While it was previously assumed that the main role of the MR was to facilitate 
phagocytosis of pathogens, there is limited published evidence to support this. 
Different attempts have been made to ‘knock-in’ phagocytic activity into non-
phagocytic cells through transfection of the MRC1 gene (coding for the MR) with 
limited success 200. Given the ability of MR to also recognise a number of 
glycoproteins, another key function of the receptor likely involves matrix 
remodelling 203. This is supported by evidence that MR expression is closely aligned 
to a macrophage phenotype that exhibits a high scavenging and remodelling 
capacity 204. This type of activity includes removal of lysosomal enzymes, 
myeloperoxidases and tissue plasminogen activator 195.  
 
The MR has been considered a valuable target in work to try and manipulate the 
function of macrophages in vivo, potentially halting or reversing a number of 
inflammatory diseases. However, the typical routes to polarising macrophages in 
vitro show little translational potential to humans in vivo, as pulsing with cytokines 
would almost certainly have adverse and off-target effects 205. This has led to 
investigation of alternative ways of promoting macrophages to shift inflammatory 
phenotype in situ 206,89. A recent paper demonstrated the use of a nanoparticle 
system designed to specifically instigate clustering of the macrophage mannose 
receptor 205. In a pre-clinical model of mouse bone-marrow-derived macrophages 
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(BMDM), a gluco-mannan nanoparticle appeared to induce an anti-inflammatory 
macrophage phenotype – inferred through expression of IL-1 and arginase.  
 
Another approach to target the MR involved its association with the tumour 
microenvironment and its expression on tumour-associated macrophages (TAM) 207. 
In many different tumour types, there is often macrophage infiltration that is 
associated with tumour progression 208,209. These TAMs assist in tumour growth by 
adopting a phenotype that promotes matrix remodelling and angiogenesis 210. Work 
by Movahedi et al. found a specific subset of TAMs, which express low levels of MHC 
II, acting as a highly angiogenic cell type that would assist in tumour growth 211. The 
MR is consistently upregulated in MHC II low macrophages, thus representing a target 
for identifying TAMs 207. Movahedi et al. sought to target the mannose receptor by 
using an antibody-based technique 212. However, whilst conventional antibody-
based approaches are highly specific and the gold standard in targeting cell surface 
receptors, there are limitations when considering it for in vivo use. These drawbacks 
include likely off-target, Fc-related binding, as well as poor penetration in tissues 213. 
One approach to overcome this was to use a camelid nanobody as the targeting 
ligand. Like human mAb, nanobodies have a high affinity for their target. However, 
they constitute only the variable fragment of a heavy-chain only antibody and are 
only a tenth of the size of monoclonal antibodies (around 15 Kda)- so are cleared 
from the body rapidly when used in vivo 214. Other useful properties of nanobodies 
include: close identity to the VH3 domains of human antibodies, thus having low 
immunogenicity; being highly soluble and stable in extreme pH and temperature 
ranges 215. The small size and single-binding domain allow nanobodies to overcome 
the challenges usually present with antibody targeting, making them better 
equipped for tissue penetration and target specificity for in vivo applications 215. 
Movahedi et al. developed a camelid nanobody specific to an extracellular domains 
of the MR 216. Their work demonstrates use of this nanobody as a radiolabel and 
fluorescent label to identify MHC II low TAMs 212.  
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The draw of the MR as a target for tracking TAMs present at cancer sites led to the 
commercialisation of a receptor-binding pharmaceutical, Tilmanocept. This 
synthetic tracer is made up of multiple units of mannose bound to other sugars that 
can serve as binding sites for radiotracer labelling 217. Tilmanocept was designed to 
specifically label TAMs in the tumour microenvironment. The efficacy of this probe 
has been shown through phase 3 clinical trials, while complementary in vitro work 
validate its mannose receptor specificity towards human MR-positive macrophages 
218.  
 
In addition to serving as a marker for TAMs, the MR has been used as a target for 
tracking macrophage involvement in atherosclerosis, particularly with respect to 
their involvement in plaque instability 219. Building on previous work showing that 
the mannose receptor is highly expressed by macrophages associated with 
vulnerable plaques (which could indicate high risk of thrombosis), a near infra-red 
optical imaging agent was developed by Kim et al. to label macrophages during 
atheroma, to be imaged using optical coherence tomography (OCT) 220. The probe 
described in their work was composed of mannosamine (an MR ligand) connected 
to maleimide via a PEG linker and conjugated to either a Cy 5.5 or Cy 7 fluorophore. 
This probe showed successful labelling of macrophages when imaged with an OCT 
system 219. 
 
Looking beyond using the MR as a proxy for only detecting the presence of 
macrophages, additional studies have involved quantifying the expression of the 
receptor as a way to monitor the response of macrophages to different therapies for 
treatment of inflammatory disease. One example involves methods to manipulate 
macrophage cell activity to alleviate the pathology of chronic obstructive pulmonary 
disease (COPD). During COPD, there is dysregulated apoptosis and macrophage 
dysfunction in the airways 77. Alveolar macrophages show defective clearance of 
apoptotic cells during COPD, while there is a net increase of apoptotic material and 
secondary necrosis that exacerbates the inflammatory response 191,221. Therefore, 
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efferocytosis is postulated to be a key process to manipulate in order to improve lung 
function for COPD patients 88,222. Low doses of macrolide antibiotics such as 
azithromycin have shown clinical benefits with inducing anti-inflammatory 
responses 223. Azithromycin has also been shown to improve the efferocytosis 
function of AMs 224. In one study, azithromycin increased MR expression by 50% in 
vitro, while using an MR blocking antibody reduced the phagocytic capacity of AMs 
by 60% 107.  This shows the potential to use expression of the MR as a proxy for 
macrophage phenotype, including the restoration of cell activity that was lost in 
disease. 
 
The hypothesis for this chapter was a fluorescent nanobody probe can selectively 
label mature human macrophages via the mannose receptor and profile their 
inflammatory phenotype. As it is the first iteration of a MR-nanobody probe 
developed by our group, the aims of this chapter focus on the early biological 
characterization of the MR-nanobody: determine the cell and target specificity as 




4.2 Use of an MR-Nanobody to selectively label macrophages 
 
A mannose receptor-specific nanobody which has been previously described was 
acquired for the purposes of developing a macrophage-specific optical probe 216. The 
nanobody is from camelid origin, developed through immunisation with 
commercially available extracellular domains of the human mannose receptor. The 
nanobody was subsequently isolated from a phage display library. Four fluorophores 
of sulphonated Cyanine 5 (SCy5) were conjugated to the nanobody scaffold to yield 
a far-red fluorescent MR-nanobody (Fig 4.1A), synthesised by Gavin Birch (Bradley 
Group, University of Edinburgh).  
 
The MR-nanobody construct was first assessed with viable human monocyte-
derived macrophages to determine cellular labelling. Using confocal microscopy as 
shown in Figure 4.1, MR-nanobody labelled MDMs in a concentration dependent 
manner. Using 50 nM of MR-nanobody provided a significantly higher signal than 
other concentrations, with a good signal to noise ratio (Figure 4.1D). As a result, the 
50 nM concentration was considered the most appropriate for further experiments. 














Figure 4.2 MR Nanobody selectively labels differentiated macrophages. 488 nm imaging panels represent cell 
labelling with Cell Tracker CMFDA as a counterstain. 633 nm imaging panels represent labelling by the MR-
nanobody. Peripheral blood monocytes show minimal labelling signal when imaged. Differentiated monocyte-
derived macrophages after 6 days of culture show greater fluorescent labelling. Plots to the right represent 
complimentary flow histogram analysis of MR Nanobody labelling for each cell type. Dotted lines represent 50 
nM Cy5 dye control and solid plots represent MR-nanobody labelling. Images were taken by a CLSM and are 
representative of repeated FOV from three experimental repeats. 
 
This analysis was repeated with a positive control antibody for mannose receptor 
labelling. An CD206 monoclonal antibody (BD Biosciences), conjugated to a PE 
fluorophore, as used in chapter three to determine mannose receptor expression 
(Figure 3.2). Figure 4.3 shows that, with the commercial anti-CD206 antibody, the 
staining pattern is similar to that of the MR-Nanobody. There was minimal labelling 
of monocytes when imaged with confocal microscopy, which was increased with 
differentiated macrophages. The representative flow histograms in Figure 4.3 show 
that for monocytes, there was minimal signal from the anti-CD206 antibody when 
compared to a PE isotype control. CD206 antibody binding was increased markedly 
with differentiated macrophages. The confocal imaging of MR-nanobody labelling 
of macrophages displays a similar staining pattern to that of the anti-CD206 
antibody, with punctate labelling throughout the cell. This observation suggests that 
the majority of the MR-nanobody labelling appears within cells, rather than the cell 
surface. This could be representative of early endosomal compartmental labelling, 


































Figure 4.3 Anti-CD206 IgG monoclonal antibody selectively labels mature macrophages. Peripheral blood 
monocytes show no fluorescence labelling. Differentiated monocyte-derived macrophages after 6 days of 
culture exhibit fluorescent labelling. CMFDA dye was used to counterstain cells. Images were taken by a CLSM 
and are representative of repeated FOV from two experimental repeats. Flow cytometry histograms show 
labelling of anti-MR antibody (red) in comparison to an isotype control (grey). 
 
4.2.2 MR-Nanobody labels broncho-alveolar lavage cells  
 
The potential of the MR-nanobody to label a more biologically relevant primary 
human macrophage population, rather than in vitro MDMs, was also assessed. 
Broncho-alveolar lavage (BAL) samples were collected from aged patients (with 
suspected idiopathic pulmonary fibrosis) undergoing routine bronchoscopy at the 
Royal Infirmary of Edinburgh. Figure 4.4 shows the cellular cytospin of the BAL 
sample revealing that, as would be expected in a BAL sample, over 90% of the cells 
present had a morphology consistent with that of an alveolar macrophage (large 
cytoplasm and single nucleus). These BAL cells were labelled with both the MR-
nanobody and PE anti-CD206 monoclonal as a positive control for mannose receptor 
labelling and examined by immunofluorescence microscopy. Figure 4.4 shows that 
the MR-nanobody labelled the cells in the BAL sample. The staining pattern shown 
from confocal microscopy revealed similarities between the MR-nanobody and the 





























4.2.6 MR-Nanobody shows no off-target labelling of lung epithelial cells but off-
target labelling of human granulocytes 
 
Further cell-type specificity assessments were carried with other cell types 
representative of those that would be found in the alveolar space. This is important 
for the characterisation of the MR-nanobody as a potential imaging probe to be used 
in vivo, to demonstrate its labelling is specific to macrophages. The human 
carcinoma A549 cell line was used as a model to monitor how the MR-nanobody 
interacts with human alveolar epithelial cells. Figure 4.8 shows that the MR-




Figure 4.8 MR Nanobody shows no off-target labelling of a alveolar epithelial cell line. Representative images 
show that MR Nanobody does not label A549 cell line. The 633 nm image shows the MR-Nanobody fluorescent 








I next examined labelling of other immune cell types by using human 










The expression of the MR has  been suggested to align to certain macrophage 
phenotypes, or represent a marker to track the manipulation of their phenotype 
away from an inflammatory state 196. In chapter three, receptor expression profiling 
of macrophages following different polarising stimulants did not significantly alter 
expression of the mannose receptor (CD206) (Figure 3.3). While it could be expected 
that the MR-nanobody would yield the same result, it would still be worthwhile to 
assess MR-nanobody labelling of polarised macrophages, as a nanobody ligand may 
be a more sensitive indicator of altered receptor recycling activity. MDMs were 
polarised into different activated states: a pro-inflammatory phenotype through 
interferon-gamma (IFN) and lipopolysaccharide (LPS) stimulation, or an anti-
inflammatory phenotype through interleukin-4 stimulation. Figure 4.10 shows that, 
from flow cytometric analysis, the labelling of the MR-nanobody showed little 
difference between either of the polarised macrophage phenotypes when compared 
with an untreated control MDM population. This observation was supported by 
confocal imaging that shows similar labelling patterns by the MR-nanobody of the 




Figure 4.10 MR nanobody labelling of polarised human monocyte-derived macrophages (MDMs). Human MDMs 



























4.2.9 Transfecting the mannose receptor into a negative cell type does not confer 
MR-nanobody labelling 
 
An alternative method of determining target specificity of the MR-nanobody would 
be to ‘knock in’ expression of the receptor into a negative cell line – via a transfection 
– and assess whether this aligns with labelling of the MR-nanobody probe. To do 
this, the Chinese Hamster Ovary (CHO) cell line was transfected with an expression 
plasmid containing the human MRC1 gene (Origene, MI, USA) using a transient 
lipofectamine-based transfection technique. Figure 4.12 shows that, following 
transfection, the CHO cell population showed expression of the mannose receptor 
when analysed with an anti-CD206 monoclonal antibody together with flow 
cytometry. In contrast, no-plasmid “control” population of CHO cells showed no 
expression of the receptor. However, it was not possible to show labelling of the MR-
transfected CHO cells with the MR-nanobody (compared to a Cy5 dye only control) 








The results of this chapter showed the early biological characterisation of a 
fluorescently labelled nanobody construct intended to specifically target the 
macrophage mannose receptor. The MR-nanobody construct demonstrated cell-
type specificity towards macrophages, with a similar staining pattern to that of 
commercial monoclonal antibodies for the same mannose receptor target. This 
demonstrates the potential of this novel probe construct: a macrophage-specific 
probe that features biochemical properties – attributed to the nanobody – that 
would allow safe use in a clinical setting. Characterisation of this probe will lay the 
foundation of carrying out macrophage receptor phenotyping in humans, in situ, for 
the benefit of experimental medicine.  
 
4.3.1 Cell-type specificity of the MR-nanobody 
 
At nanomolar concentrations, the MR-nanobody specifically labelled human 
monocyte-derived macrophages, with a high signal to noise ratio, despite no wash 
step. The high affinity of the MR-nanobody for macrophages would be of critical 
importance for labelling cells in the alveolar space in humans, in vivo, which 
represents a far more complex environment than an in vitro situation.  
 
In addition, the MR-nanobody also labelled primary human bronchoalveolar 
macrophages, demonstrating the potential to label macrophages in situ. Previous 
work has demonstrated relatively high expression of the mannose receptor on AM 
highlighting its potential  for targeting AMs in vivo 225. 
 
The MR-nanobody did not show differential labelling of MDM polarised into 
different inflammatory phenotypes, even though receptor profiles of the MDM 
demonstrated that polarisation had been induced (see chapter 3, Figure 3.3). 
Similarly, the expression of MR was not altered on polarised MDM populations.  This 
 106
observation is antithetical to previous reports of modulating the mannose receptor 
expression on macrophages in vitro 196. Others have found that stimulating 
macrophages with IL-4 elicited a higher expression of the mannose receptor, while 
the reverse occurred when stimulating with interferon gamma 226,227. It is possible 
these different results could be due to differences between mouse (3, 24,25) and 
human cells (this study). In addition, it is possible that there is some variability of 
human macrophage phenotypes following in vitro cytokine stimulation. 
 
The MR-nanobody appeared to specifically label MDMs, but not their monocyte 
precursors. This observation is consistent with data shown in Chapter 3 (Figure 3.2) 
and the work of others, that the mannose receptor was only expressed on MDM.202. 
It was worth noting some technical discrepancies in MR-nanobody labelling of 
monocytes. While confocal microscopy analysis revealed minimal signal with 
monocytes, flow cytometry analysis showed low level MR-nanobody labelling. Thus, 
flow and confocal data could lead to different conclusions about the level of off-
target labelling of this probe. One explanation for this is the differences in sensitivity 
between the two optical systems (flow cytometry and confocal imaging). The flow 
cytometric analysis may be detecting MR-nanobody binding to monocytes that 
would not be seen on an imaging system. Monocytes are capable of fluid-phase 
pinocytosis and therefore a proportion of this population could non-specifically 
internalise the MR-nanobody – though to a much less degree as the more activate 
internalisation processes happening with mature macrophages 225.  
 
The cell-type specificity aspect of this work uncovered what appeared to be off-
target labelling by the MR-nanobody when incubated with human neutrophils when 
imaged with confocal microscopy. The labelled cells  were  morphologically distinct 
from those that were negative, with a stretched, flattened morphology 
characteristic of an activated neutrophil 228. This observation may reveal an issue 
with using a fluorescent probe in the presence of activated neutrophils which exhibit 
altered surface charge and increased membrane porosity. The activated neutrophils 
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also stained when incubated with Cy5 fluorophore alone, possibly due to the Cy5 dye 
“sticking” to the activated cell membrane. It could also be that activated neutrophils 
increase fluid-phase pinocytosis, accumulating fluorophore inside the cell non-
specifically 229. As each MR-nanobody probe has multiple cyanine 5 fluorophore 
units attached, accumulation of probe inside the cell would yield a much higher 
signal than that of free dye. It would be important to assess the effects of blocking 
neutrophil pinocytosis in order to test this hypothesis. This could be achieved by 
blocking the activity of PI3 kinase within the cell (such as Wortmannin) or using 
micropinocytosis blockers such as Dynasore (an inhibitor of dynamin activity), to 
show the effect this has on the off-target labelling of the MR-nanobody 230, 231. It 
could then be possible to delineate the different routes the probe takes when 
labelling neutrophils and macrophages, testing whether the route of internalisation 
with neutrophils is non-specific, while a more active process governs uptake of the 
probe by macrophages.  
 
4.3.2 Target specificity of the MR-nanobody 
 
Work in this chapter also sought to define the target specificity of the MR-nanobody. 
The MR-nanobody binds to an epitope on the extracellular domain of the mannose 
receptor. Characterisation of the MR-nanobody probe should show that conjugation 
of a fluorophore - cyanine 5 or any other alternative fluorophore in future iterations 
- does not interrupt epitope binding of the nanobody. The initial attempt at 
determining target specificity was to competitively inhibit the MR-nanobody from 
binding to the mannose receptor. To do this, the probe was incubated with human 
MDMs in the presence of excess mannan – a known ligand for the mannose receptor. 
This form of competitive inhibition has been used previously to validate the target 
specificity of other mannose receptor probes 218. However, excess mannan did not 
diminish MR-nanobody labelling of MDMs. One reason for this could be the nature 
of ligand-receptor interactions and the different binding routes taken by mannose 
and the MR-nanobody when interacting with the receptor. The extracellular domain 
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on the mannose receptor the nanobody binds to has not been reported, therefore it 
could bind independently of the  carbohydrate-recognition domains that recognise 
mannan 232. There are several extracellular domains on the mannose receptor, 
including the  cysteine-rich domain or the fibronectin domains that may contain the 
epitope that the nanobody binds to  200. It should also be noted that the excess 
mannan in this competition assay may actually have had the reverse effect on the 
MR-nanobody. Preliminary data, based on two experimental repeats, suggested 
that excess mannan slightly increased the levels of MR-nanobody labelling. This 
could in fact be a functional response of increased mannose receptor activity in the 
presence of a ligand. Previous studies have found that the majority of this endocytic 
receptor exists within the cell, in endosomal compartments 196. The recycling 
capacity of the receptor can dynamically change in response to ligand binding 233. 
Therefore, having excess mannan in the cell media may stimulate a higher 
proportion of receptors being present on the cell surface – with a greater number of 
epitopes for the MR-nanobody to bind to. 
 
Further target specificity analysis using CHO cells that had been transfected with the 
mannose receptor expression revealed that despite positive staining with a CD206 
mAb post-transfection, the MR-nanobody was unable to label the transfected CHO 
cells. Although one conclusion would be that the MR-nanobody is not target specific, 
it would be important to demonstrate that the transfected receptor retained 
structural integrity,  complete with epitope for MR-nanobody binding 234. In 
addition,  the functional capabilities of the transfected receptor could be explored: 
this could be achieved through fluorescently labelling mannosylated compounds to 





4.3.3 Characterisation of mannose receptor probes 
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As outlined previously in this chapter, the mannose receptor has already been 
established as an imaging target for probes to specifically label macrophages – some 
even using the same nanobody-based targeting ligand 216. As this chapter seeks to 
add to our understanding of probing macrophage heterogeneity using the mannose 
receptor, it is worthwhile to consider the similarities and differences with how this 
work validated the MR-nanobody and approaches taken by others. The most 
prominent example of an MR-targeting probe is Tilmanocept, a radiolabelled probe 
to target macrophages via the mannose receptor 218. Rather than using an antibody-
based ligand, Tilmanocept uses mannose sugars to target the receptor. The in vitro 
characterisation for Tilmanocept used a similar model to that used in this body of 
work: human monocyte-derived macrophages cultured in autologous serum 218. The 
primary function of Tilmanocept is to label tumour-associated macrophages present 
in lymph nodes. Taking a similar approach to work in this chapter, flow cytometry 
was used to demonstrate the cell-type specificity of a cyanine 3 labelled 
Tilmanocept. Validation of Tilmanocept in vitro used mannan competition as a way 
to determine target specificity of the probe towards the mannose receptor 218. 
Unlike the MR-nanobody described in this chapter, fluorescently labelled 
Tilmanocept was blocked from labelling human MDMs in the presence of the 
concentration of mannan used in my study. The authors also used ‘knock down’ of 
the mannose receptor via siRNA  to show that macrophages require MR expression 
for Tilmanocept labelling, while transfection of the MRC1 gene into HEK cells 
showed Tilmanocept labelling increased when ‘knocking in’ the mannose receptor 
218. In their initial in vitro validation of a  fluorescently conjugated MR-nanobody 216 , 
Movahedi et al.  used isolated macrophages from mouse models of lung and breast 
carcinoma. Using the nanobody ligand conjugated to commercial fluorophores 
(AlexaFlour488 and 647), they showed cell-type specificity towards a specific subset 
of tumour-associated macrophages that were MHC II low, while all other myeloid cells 
in a tumour sample – including granulocytes – were negative for labelling 216. They 
also sought to determine target specificity of the nanobody by using an MR-
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knockout mouse model to show mannose receptor expression was required for the 
nanobody to label. In addition, they also used a control nanobody structure with no 
affinity for macrophages, to show that nanobody binding to the macrophages was a 
specific process 216.  
 
4.3.4 Limitations of the work in this chapter and conclusion 
 
The work in this chapter describes studies to characterise a novel approach to 
optically profiling macrophages and validate its potential for specifically targeting 
macrophages via the mannose receptor. Ultimately there were some limitations to 
how confidently that assessment could be made.  
 
First, it would have been useful to have additional controls in place to determine the 
target specificity of the MR-nanobody. Use of macrophages lacking mannose 
receptor expression would have confirmed whether the MR-nanobody labelling 
required the MR or another pathway. Acquiring another, non-specific, nanobody 
construct and carrying out the same fluorophore conjugation would aid in discerning 
if macrophages non-specifically internalise these compounds or whether labelling 
represents an active process.  
 
Second, it was not possible to explore if the choice of fluorophore had an impact on 
the function of the probe. The MR-nanobody described in this chapter was 
conjugated to four far-red cyanine 5 (sulphonated) dyes. Alternative fluorophores 
across the visible spectrum possess a variety of properties: they can vary in their size, 
their charge properties, and their solubility. This can lead to significant 
consequences in terms of probe function. In the context of using a nanobody – a 
compound only 15 kDa in size – the size of the fluorophore conjugated to the 
fragment could significantly impact on its ability to bind to its epitope 235. For 
example, the fluorophore nitrobenzodioxazole (NBD) has been popularised for use 
in imaging probes due to its small size 236,237. One drawback of using NBD is its 
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limited spectral properties, often emitting only in the “green” window of the visible 
spectrum. One reason this fluorophore was not initially considered for labelling the 
MR-nanobody is due to this emission, as it would overlap significantly 
autofluorescent tissue of the human lung 131. However, recent work has looked to 
expand the spectral characteristics of small fluorophores, such as NBD, which may 
align well with future iteration of the MR-nanobody 238. 
 
Work in this chapter showed that not only the MR-nanobody probe, but also free 
cyanine 5 dye in solution would ‘stick’ to polymorphonuclear cells. Therefore, 
interchanging the fluorophore on the MR-nanobody could shed more light on its 
non-specific labelling of neutrophils and possibly its ability to bind to the mannose 
receptor. 
 
Despite these limitations, this chapter presents the MR-nanobody, with a far-red 
fluorescence, as a novel probe that shows cell-type specificity towards 
macrophages. The work shows that labelling mostly occurs through internalisation 
by cells in an active process. It also shows that primary human alveolar macrophages 
can be labelled by this probe. This chapter lays the foundation for using a fluorescent 
nanobody to target macrophages in the human lung, to be used in combination with 



























 Chapter Five: Imaging Macrophage 
Phagocytosis Using Optical Endo-microscopy 















5.1.1 Novel markers for non-invasive profiling of macrophage phenotype and 
activity 
 
The traditional methods of profiling macrophage phenotypes – whether they align 
to pro-inflammatory or pro-resolving states – have typically involved quantifying the 
expression of known markers to activated phenotypes 55. Some of these are outlined 
in chapter three, such as cell surface receptors indicating pro-inflammatory 
phenotypes (CD80) or pro-resolving phenotypes (CD163). Other approaches can 
also include quantifying cell products such as iNOS and Arg1, or gene expression 239. 
A challenge in experimental medicine is how the phenotype of macrophages could 
be profiled while the cells are still in situ. Chapter four presents a novel fluorescent 
nanobody that targets the mannose receptor, which is associated with certain 
macrophage phenotypes, with the potential to be used in situ 216. This still involves 
the use of an exogenous probe to identify macrophages based on cell-surface 
marker expression. However, there are other endogenous markers on macrophages 
that could allow for even more minimally invasive methods of profiling.  
 
The metabolic state of macrophages – whether their main form of energy 
production is via aerobic glycolysis or oxidative phosphorylation – can align with 
what activated state the cells are in 240. Pro-inflammatory macrophages favour 
aerobic glycolysis, while anti-inflammatory cells favour oxidative phosphorylation 
241. A key molecule involved in both forms of energy production is the coenzyme 
NADH, which is present in different forms depending on the metabolic activity of 
the cell 242. During glycolysis, NADH is unbound in the cytoplasm of the cell; during 
oxidative phosphorylation, NADH is bound to mitochondrial shuttles 243. NADH is an 
inherently autofluorescent molecule, which can serve as a maker for label-free 
imaging of macrophages 244. More importantly, the binding state of NADH dictates 
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the measurable fluorescence lifetime of the molecule, providing a quantifiable, 
label-free way to determine a macrophage’s polarised state 243,245. Studies have  
demonstrated the potential of using fluorescence-lifetime imaging microscopy 
(FLIM) as a quantifiable method of determining the metabolic state of macrophages, 
in vitro following polarisation 243. One study showed that different FLIM signatures 
aligned with other markers for polarised states, such as iNOS production following 
IFN and LPS stimulation, or Arginase production following stimulation by IL-13 and 
IL-4 243. However, it is necessary to note this work was using an in vitro model of 
mouse bone-marrow derived macrophages in extreme polarised states, which may 
not reflect how human macrophage phenotypes would present in vivo.  
 
Other methods of interrogating macrophage phenotypes using endogenous 
markers, label-free, have been used in the context of the tumour microenvironment. 
It has previously been established that characterisation of macrophage phenotypes 
surrounding a tumour has a close relationship with a patient’s clinical outcome, even 
the potential efficacy of some treatments 246,247.  One study used hyperspectral 
imaging (HSI) as a label-free way to classify known macrophage phenotypes 248. 
Using a combination of imaging and spectroscopy, HSI provides complete spectral 
information for every pixel of an image 68. Their aim was to provide a fingerprint of 
macrophage phenotypes based on morphological and spectral detail from polarised 
human macrophages in vitro, using visible light and NIR reflectance 248. Analysis of 
the different spectra revealed tangible differences between macrophage polarised 
states, though variability in data between human donors exemplified the challenge 
of aligning this system for translational purposes. 
 
As more evidence suggests that the plasticity of macrophages, including those in the 
alveolar space, may complicate the intended results of therapies, it is becoming 
increasingly important to understand exactly how these cells respond to drugs in situ 
249. This is because it would be difficult to account for all the factors that contribute 
to macrophage plasticity in their native environment, such as the alveolar space. 
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This requires imaging systems in place that are capable of carrying out this form of 
interrogation. 
 
5.1.2 Potential of in situ profiling of human AMs 
 
Despite advances in the profiling of macrophage activity, there remains a challenge 
to effectively profile these cells in situ. AMs exemplify this as it is difficult to access 
the distal region of the alveolar space where they reside  250. Therefore, it has not 
been possible to profile alveolar macrophage activity while they are still in their 
native environment. However, there are now imaging systems available that can 
overcome this challenge. Developments in optical microendoscopy (OEM) has led to 
widefield and confocal fluorescence-based imaging systems 131,130. These systems 
use fibre imaging bundles small enough to access and image the distal regions of the 
human lung 129,127. In a clinical context, this form of imaging can be incorporated into 
routine bronchoscopy and may provide further structural and molecular information 
about a patient’s lung pathology 131. The autofluorescence of elastin in lung tissue 
means the structure of the lung is readily imaged with fluorescence-based systems 
and can direct the fibre-imaging bundles to the alveolar space for interrogation 131. 
OEM presents an opportunity to align these systems - capable of directly imaging 
inside the alveolar space - with imaging of alveolar macrophages in situ. Moreover, 
using fluorescence means there is scope to perform multiplex imaging; to image in 
a range of colour wavelengths, with potential to specifically label cells to detect over 







5.1.3 Autofluorescent challenge of imaging AMs 
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However, there lies a challenge to using fluorescent microscopy in the alveolar 
space.  This environment already presents large amounts of autofluorescence from 
the lung tissue, but also from resident cells. Evidence shows that AMs in particular 
can be highly autofluorescent 251,252. Autofluorescence from macrophages can derive 
from NADH within the cell, but also other co-enzymes such as riboflavin and flavin 
253,254. This characteristic has long been used to isolate alveolar macrophages using 
flow cytometry 255. Autofluorescence appears to be exacerbated in AMs from a 
smoker 251. It has previously been shown that the tar component of cigarette smoke, 
which is highly autofluorescent, is a likely contributor to the high amount of 
macrophage autofluorescence 256. Having this amount of autofluorescence in the 
lung can limit the use of exogenous fluorescent probes to effectively carry out 
molecular imaging in this region 257. While there are methods to minimise cellular 
autofluorescence in vitro, such as use of crystal violet as a quencher, this would not 
be feasible in the context of profiling macrophages in situ 258.  
 
The ability to interrogate the activity of COPD AMs from a smoker in situ would be 
of high value in the context of experimental medicine. It could be used to confirm 
phagocytic defects of these cells in situ, even monitor the effects of potential 
therapies targeting the cells without removing them from the alveolar space. 
Previous studies in vitro have shown that smoking exacerbates the phagocytic defect 
of alveolar macrophages during COPD 83,222. Therefore, routes to overcome the 
challenge of smoker’s macrophage autofluorescence would have to be explored to 
effectively profile these cells in situ. There has recently been described a novel OEM 
system that incorporates multispectral unmixing capabilities 147. It has already been 
used to image inside the human alveolar space, spectrally unmixing autofluorescent 
lung tissue and fluorescent probes to detect bacteria. It is possible this system may 
be used to mitigate the autofluorescence of alveolar macrophages in the lung and 
spectrally separate this autofluorescence from exogenous fluorophores introduced 
to this space 147.  
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The hypothesis for this chapter is that optical endomicroscopy combined with 
spectral ratio imaging can image autofluorescent alveolar macrophages label-free 
and profile their phagocytic activity using labelled targets. The aims were to: 
characterise imaging of labelled macrophages using an OEM imaging system and 
develop an assay to validate use of a fluorescent and spectroscopy-based imaging 
setup to profile phagocytosis of highly autofluorescent alveolar macrophages from 
smoker’s with COPD. 
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5.2 Profiling phagocytosis with OEM 
 
The work in chapter three described standard techniques to profile the phagocytic 
activity of macrophages. While it showed to be an effective method of quantifying 
phagocytosis and any modulators to activity, the flow-cytometric technique is still 
limited to profiling cells in vitro; it can’t be used to profile AMs in their native 
environment. This chapter will outline the preliminary work undertaken to explore 
how macrophage phagocytosis may be profiled in situ, using novel OEM imaging 
systems.  
 
5.2.1 Using wide-field fibre-based endomicroscopy to image phagocytosis 
 
A three colour, widefield OEM imaging platform – named Versicolour - has been 
previously described and characterised for the application of imaging the alveolar 
space 130. For the initial work to show this system could also profile the phagocytic 
activity of macrophages, the same assay described in chapter three was carried out. 
This involved incubating MDMs with apoptotic neutrophils, labelled with pHrodo 
Green STP ester. In order to visualise all macrophages in the field of view, Syto 61 
Red nuclear stain was used to label the macrophages. The pH sensitivity of the 
pHrodo dye was used as a marker for acidification of a phagolysosome (therefore 
phagocytosis taking place) and cytochalasin D was again used as a negative control 
for phagocytic activity. Versicolour has a 470 nm blue LED and a 625 nm red LED to 
excite pHrodo Green and Syto 61, respectively. The distal end of the imaging fibre 
bundle (connected to Versicolour) was touched against the surface of the culture 
plate wells the macrophages were adhered to. Figure 5.1 shows representative 
images using Versicolour following a 45 min incubation between the macrophages 
and apoptotic neutrophils. Without cytochalasin D present, there are a number of 
red-labelled macrophages that also exhibit green fluorescence, indicative of pHrodo 
Green signal (Figure 5.1A). This green fluorescence is knocked down in the presence 
of cytochalasin D (Figure 5.1B). This shows that Versicolour, a widefield OEM system 
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imaging of phagocytic targets 259. Any fluorescent imaging in the alveolar space is 
exacerbated further by the inherent autofluorescence of lung tissue, namely the 
elastin and collagen structures 131. The AMs of COPD smokers in particular are often 
defective in their phagocytic function and are an attractive target for designing 
therapies to restore activity 83,224. Therefore, it would be worthwhile to overcome 
the autofluorescent challenge posed by these macrophages, in order to identify 
those which also exhibit pHrodo fluorescence as well as their own autofluorescence. 
This would aid in efforts made in experimental medicine to profile these cells in situ. 
 
5.3.1 A novel imaging system combining spectral ratio and OEM 
 
A novel OEM imaging system has been designed and characterised to overcome the 
autofluorescent challenges faced when imaging in the alveolar space 147. This system 
was developed and built by Helen Parker (University of Edinburgh) who has 
collaborated on work in this chapter to apply the profiling of phagocytosis to her 
imaging setup. The setup is described in Figure 5.2, with some similarities and 
differences to the Versicolour widefield OEM. Both systems incorporate an imaging 
fibre to capture fluorescence and LED excitation sources. However, the spectral ratio 
(SR) system only uses one colour, a blue 470 nm LED. The SR system also differs 
from Versicolour by incorporating an ‘optical chopper’ and a dichroic mirror that 
splits emitted fluorescent light at 605 nm wavelength. This means that all 
fluorescent light that is emitted following excitation by the 470 nm LED is split into 
two channels: the short channel - incorporating all light under 605 nm - and long 
channel - incorporating light over 605 nm. While many fluorescent objects will be 
spectrally similar when excited with the same light source, they will have different 
intensities across the short channel and long channels defined by the SR system. The 
relative intensities in both channels for a fluorescent object can be transformed into 
a single spectral ratio value that can be assigned to a false-colour scale. Mapping 
different spectral ratio values across a new colour scale can enhance the contrast 




Figure 5.2 A spectral ratio OEM imaging system, developed by Helen Parker, University of Edinburgh. A bespoke 
imaging fibre is coupled to a blue 470 nm LED via a dichroic mirror. Any emitted fluorescent is passed up from 
the distal end of the imaging fibre to a second dichroic mirror at 605 nm. Emitted light over 605 nm is passed 
through an optical chopper and recombined with another dichroic mirror onto a monochromatic camera. A PC 
is used to control a triggering unit with outputs to the camera and the chopper. Schematic and description 
adapted with permission from Helen Parker. 
 
This technique has the potential to enhance the contrast between spectrally similar 
objects in the human lung, namely lung tissue and AMs. Figure 5.3A shows the 
fluorescent emission spectra overlay of each. The emission of AMs is an average of 
three populations of macrophages isolated from BAL of COPD patients. The lung 
tissue emission was taken from the boundary tissue of lung cancer resections. The 
emission plots show their autofluorescence is similar, both peaking at ~550 nm . The 
AM emission maintains a slightly higher intensity across the higher wavelengths 
compared to lung tissue autofluorescence. Figure 5.3B shows what the spectral ratio 
value of each would be if their intensities were divided into short and long channels 
at different wavelength cut-offs. The plot shows that the higher the cut-off 
wavelength, the more distinct their spectral ratio values would be. The cut-off 
wavelength in the SR system is 605 nm. At this cut-off, the spectral ratio value of 
lung tissue would be ~2.5 (arbitrary units), while the macrophage value would be ~5. 
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Therefore, if these values were assigned to a false-colour image scale, they would 
appear as distinct colours. 
 
 
Figure 5.3 Emission spectra of alveolar macrophage and lung tissue autofluorescence. Human alveolar 
macrophages were freshly isolated from broncho-alveolar lavage fluid and their autofluorescent spectrum was 
measured using an imaging fibre connected to a commercial spectrometer, exciting at 470 nm. A) The 
macrophage spectrum was overlaid with the autofluorescent emission spectrum of human lung tissue. The 
normalised intensity of the two spectra differ at the cut off wavelength of 605 nm (shown on the dotted line). B) 
The spectral ratio values generated from their emission spectra result in different values for macrophages and 
lung tissue across a range of wavelengths. At the defined cut-off wavelength of 605 nm, lung spectral ratio value 
is ~2.5; macrophage spectral ratio value is ~5. The autofluorescence emission of macrophages and lung tissue 
are representative of emission measurements taken from three independent patient cells. The plot in panel B 
has been created by Helen Parker. 
 
Figure 5.4 shows how the application of SR works in practice, when imaging the 
alveolar space of a whole ex vivo human lung model. It shows how lung tissue and 
AMs present when using single-colour fluorescence imaging (Figure 5.4A), then how 
they can be distinguished when applying SR values and a new colour scale (Figure 
5.4B). This demonstrates the potential use of SR imaging to image highly 
autofluorescent AMs in a COPD lung and differentiate them from other 












Having established the potential for spectral ratio imaging to discern macrophage 
autofluorescence from lung tissue autofluorescence. The progression of this work 
was to show that phagocytic macrophages could be identified in a population via 
internalisation of pHrodo Green-labelled targets. The amount of AM 
autofluorescence however would cause issues with identifying pHrodo signal within 
a cell. Therefore, the application of pHrodo emission to the SR setup was considered. 
Figure 5.5A shows an overlay of pHrodo Green emission, compared to AMs and lung 
tissue autofluorescence. There is a distinct shape to pHrodo Green emission 
compared to AMs and lung tissue. While their emission peaks are similar, pHrodo 
emission intensity is noticeably lower in higher wavelengths. This suggests that, as 
pHrodo emission intensity is distinct at the cut-off wavelength of 605 nm, a unique 
spectral ratio value would be applied to pHrodo. Figure 5.5 also shows the relative 
visibility of pHrodo signal against either AMs Figure 5.5B or lung tissue when 
factoring each of their SR values (Figure 5.5C)  (with a relative visibility value of 1 
being indistinguishable). These plots show that it would be possible to multiplex the 
three emissions of pHrodo, macrophages and lung tissue into separate colours on an 
SR scale. In principle, this would mean AMs could be identified label-free by their 
autofluorescence, while any phagocytic cells would present as a different colour as 






The next stage in this workflow was to show that the spectral ratio system can profile 
the phagocytic activity of highly autofluorescent AMs from a COPD smoker. AMs 
were isolated from a BAL of a smoker with COPD and adhered to the bottom wells 
of tissue culture plates. The macrophages were then incubated with apoptotic 
neutrophils labelled with pHrodo green, with cytochalasin D used as the negative 
control. Figure 5.7 shows the imaging of macrophages with and without cytochalasin 
D. There is predominantly one coloured signal shown in the field of view. Based on 
the low spectral ratio value (corresponding to more red coloured fluorescence) and 
size of the signal objects, this appears to be the autofluorescence of the AMs. The 
range of colours is limited in both images, regardless of the presence of cytochalasin 
D. The histograms below each image also portray the range of spectral ratio values, 
further indicating there is only one source of signal (from the AM autofluorescence). 
This means there does not appear to be any pHrodo signal present in the 
cytochalasin D– condition (Figure 5.7). Therefore, while the SR system could identify 
alveolar macrophages, label-free, based on autofluorescence, it was not possible to 
differentiate phagocytic cells due to a lack of pHrodo signal. It is possible that the 
phagocytic function of these cells was defective to the point where no cells were 








model was considered to aid in validating the SR system. This involved labelling 
healthy MDMs, already established as phagocytic, with a dye that would mimic the 
fluorescence emission of alveolar macrophages. The dye used was Syto 81 Orange 
nuclear dye. This dye was chosen because it can be excited to the same extent as 
pHrodo Green using the 470 nm excitation source (Figure 5.8A). Similar to AM 
autofluorescence, the emission spectrum of Syto 81 is noticeably broader than 
pHrodo green, with higher intensity at higher wavelengths, particularly at the 605 
nm cut-off used by the SR system (Figure 5.8A). This would mean that Syto 81 could 
be excited similarly to pHrodo with the spectral ratio system yet yield a different 
spectral ratio value. MDMs were labelled with Syto 81 then incubated with apoptotic 
neutrophils labelled with pHrodo Green. Figure 5.8B shows the imaging of MDMs 
alone, using their Syto 81 label to be identified. Though the resolution is poor, there 
is fluorescent signal shown from the cells. Figure 5.8C shows imaging with labelled 
MDMs following incubation with labelled apoptotic neutrophils. There are 
differences to the colour profile in this image. In addition to the pink colour, 
representing the spectral ratio value of the Syto 81-labelled macrophages, there is 
yellow signal indicating spectral ratio values of pHrodo Green (as the yellow values 
represent fluorescent signal of lower wavelengths). This indicates it is possible to 
identify all the macrophages in a field of view and discern which are phagocytic.  
 
The application of cytochalasin D was once again used as the established negative 
control for this phagocytosis assay. Figure 5.9 shows the comparison in spectral ratio 
imaging of Syto 81-labelled macrophages together with pHrodo-labelled 
neutrophils. Despite the presence of cytochalasin D, there is still a combination of 
spectral ratio value colours in the image. As previous work in this thesis has 
repeatedly validated cytochalasin D as a block on phagocytosis and subsequent 
pHrodo signalling, it would have to be inferred that the yellow signalling seen in the 







The work described in this chapter sought to provide early proof of concept for 
profiling human macrophage activity in situ. A three-colour OEM was used to image 
labelled MDMs, even detecting pHrodo-labelled neutrophils within macrophages as 
a marker of phagocytic activity. A similar OEM setup, with multispectral acquisition 
properties was used to explore potential techniques to overcome autofluorescence 
in human lung when profiling macrophages in this space. 
 
5.4.1 Imaging macrophages using OEM 
 
The three-colour imaging capabilities of Versicolour allow for multiplexing of probes 
to fluorescently label different targets. This could mean specifically labelling 
different cell types in the alveolar space. There are already probes developed by our 
group to label activated neutrophils and live bacteria using OEM in the whole lung 
model 136,134,135. Using versicolour to show the capability to perform cellular imaging 
with an in situ imaging system – and coupling that with a imaging fibre that has a 
capillary channel to deliver fluorescent probes – opens up new possibilities of 
studying cellular interactions in the lung. A green neutrophil activation probe 
previously reported could be used in conjunction with the MR-nanobody described 
in chapter four of this thesis to study macrophage-neutrophil interactions in the 
alveolar space 136. Probes to specifically label bacteria in the human lung, also 
developed by the Proteus group, could be coupled with the MR-probe to further 







5.4.2 Validation of spectral ratio OEM imaging of autofluorescent macrophages 
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This chapter begins to establish a new application for the novel SR imaging system. 
It has already been characterised with distinguishing labelled bacteria from human 
lung tissue 147. The work in this chapter sought to apply this technique to primary 
human macrophages and a labelled phagocytic target. Modelling of the emission 
spectra of human macrophages, pHrodo Green as the phagocytic marker, and 
human lung tissue with each of their SR values showed the potential of spectrally 
unmixing these largely overlapping fluorescent sources.  
 
However, a key challenge emerged when attempting to validate the SR imaging 
system: using phagocytic cells that were also autofluorescent enough to be imaged 
label-free. It was possible to validate the system image pHrodo signal (inferred as 
being inside a macrophage), or primary alveolar macrophages via autofluorescence, 
but it was not possible to image both simultaneously. There was either an issue with 
detecting cellular autofluorescence of healthy MDMs – previously established as 
being phagocytic – or difficulty detecting phagocytosis in highly autofluorescent 
primary macrophages that likely had a phagocytic defect. One workaround for this 
was to label the healthy MDMs with a cell dye that had similar spectral properties to 
primary macrophage autofluorescence. Another option could have been to isolate a 
subset of healthy MDMs that exhibited higher amounts of autofluorescence. One 
study has explored optimising MDM culture conditions to isolate this subset 252. 
Their rationale was that in vitro MDMs typically display a phenotype that makes 
them very adherent to the surfaces they grow on. However, the non-adherent cells 
in an MDM population that remained viable, displayed higher amounts of 
autofluorescence. These cells also shared microscopic characteristics of alveolar 
macrophages, such as a much more granular cytoplasm 252,255. This suggests a 
potential avenue to explore for working with viable, autofluorescent macrophages 
that can be more representative of AM autofluorescence.  
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The emission spectra of smoker’s macrophages align with a study also looking at the 
spectral characteristics of these cells 259. The emission spectra of lung macrophages 
from several patients followed a similar pattern: peaking at 550nm but having a 
broad spectrum that stretched to 700 nm 259. This spectrum is similar to that of 
tobacco tar components 259. This same study also found that this high level of 
autofluorescence was resistant to photobleaching, and non-fluorescent 
macrophages could become autofluorescent when exposed to serum from a smoker 
in culture 259. 
 
While the use of Syto 81 helped image non-phagocytic MDMs and show a range of 
spectral ratio values in the field of view, the image data when using cytochalasin D 
made it difficult to determine if the range of values included pHrodo signal. Addition 
of pHrodo-labelled apoptotic neutrophils did result in a change in spectral ratio 
values (and ultimately the false-colouring) of the macrophages in the field of view. 
However, this was unchanged in the presence of cytochalasin D. Cytochalasin D has 
been well established throughout this thesis as a negative control for phagocytosis, 
validated by knock-down of pHrodo Green signal in macrophages. However, this 
effect was not repeated using the spectral ratio system with Syto 82-labelled MDMs. 
This could be because cytochalasin D may have an effect on the spectral properties 
of the MDMs. Another, more likely, reason is cytochalasin D had an impact on the 
fluorescence of Syto 81, ultimately changing its spectral ratio value. Alternative 
controls for phagocytosis could be used, such as placing the cells at 4 ºC, to 






5.4.3 Alternative OEM systems for in situ profiling of human macrophages 
 
 135 
The challenge the SR system sought to overcome was the abundance of 
autofluorescence present in the alveolar space. This signal would interfere with 
specific labelling of macrophages and/or introducing labelled phagocytic targets to 
profile their activity. While it was not possible in the scope of this thesis, there are 
alternative OEM systems, also capable of imaging in the alveolar space in situ, that 
could take a different approach to mitigating autofluorescence. A novel two-colour 
OEM system has been developed by our group to utilise fluorescent lifetime, rather 
than intensity, as a form of imaging 260. Fluorescence lifetime imaging microscopy 
(FLIM) has been well established and used in clinical settings to distinguish between 
spectrally similar fluorescent sources 261,246. Rather than intensity, FLIM systems 
incorporate sensors that measure the decay of fluorescence – usually over a 
nanosecond timeframe – from fluorescent sources following excitation 260. This 
property is unique to different fluorophores or and endogenous fluorescent proteins 
262. A fibre-based OEM system has already been used to image human lung tissue 
and distinguish endogenous fluorescence from fluorescent probes labelling live 
bacteria 260. The ability to distinguish between macrophage activated states using 
FLIM has been previously described 243. For the purpose of profiling phagocytic 
activity, it is likely that the autofluorescence of AMs would have a different FLIM 
signature to labels of phagocytic targets, such as pHrodo. Fluorescence lifetime is an 
environmentally sensitive property, which is altered in different conditions, such as 
changes to pH 263. It is feasible that, depending on the sensitivity of a detector for 
changes in lifetime, the FLIM signature of human macrophages may dynamically 
change following phagocytosis. This may open up an entirely label-free method of 





5.4.4 Limitations and conclusions to this chapter  
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While this chapter did take an entirely novel approach to profiling macrophages, 
there were notable limitations that, if addressed, would progress this work closer to 
becoming a valuable tool in experimental medicine. First, the use of MDMs proved 
difficult when validating the spectral ratio system for profiling highly 
autofluorescent macrophages. The MDMs exhibited minimal amounts of 
autofluorescence. There was limited success in using Syto 81 to mimic AM 
autofluorescence. A more biologically relevant model should have been explored, 
such as isolated more fluorescent subset of MDMs, or instilling cigarette smoke 
products into the MDM culture 252,259. However, it would have to be determined if 
each of these methods has any impact on the phagocytic ability of MDMs, which is 
the prerequisite for using them as a model for this assay. Given the effect smoking 
appears to have on alveolar macrophage phagocytosis, instilling the products of 
cigarette smoke to MDMs may give the same effect. The second limitation to this 
workflow was the isolation of primary human AMs. There were noticeable variations 
in cell numbers and viability between BAL samples. This was determined as being 
the result of each lavage procedure not always being carried out in optimal 
conditions for subsequent isolation of cells. This led to inconclusive assays as the 
AMs were either too low in number or not viable following adherence to a culture 
dish. Third, the in vitro assay for validating OEM imaging could have been optimised 
further. The imaging was carried out in the wells of tissue culture plates, where the 
macrophages were adhered. The transparent plastic dishes contributed to some 
reflected light during the OEM imaging, particularly when using the spectral ratio 





Nonetheless, the work in this chapter describes the first use of OEM in the context 
of imaging dynamic biological events. It demonstrates the potential of using these 
types of imaging systems in the application of profiling macrophage activity. The 
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development of these assays and ultimate progression into a whole lung model 
would demonstrate the use this application could have in experimental medicine. 
Being able to profile alveolar macrophages in situ, in real-time can advance our 









































 Chapter Six: Summary and Future Directions 
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6.1 Summary of Thesis chapters 
 
The work in this thesis has concentrated on advancing methodologies aimed at 
profiling macrophages into translational assay systems. The work first established in 
vitro systems to profile human monocyte-derived macrophages, before progressing 
these systems to use methods that could be applied to studies in experimental 
medicine. The approaches taken involved characterisation of a mannose receptor 
fluorescent nanobody to selectively label macrophages and using optical 
endomicroscopy platforms to profile macrophage phagocytic activity. The findings 
from each chapter are briefly summarised below.   
 
6.1.1 Chapter three summary 
 
The purpose of the work in chapter three was to establish an in vitro system to 
differentiate human peripheral blood monocytes into macrophages. Assays using 
bench-top optical systems (flow cytometry and confocal microscopy) were used to 
establish the surface receptor phenotype and phagocytic activity of the MDMs. This 
model was to be used throughout the rest of the work in this thesis to explore novel 
ways to translate profiling of human macrophage phenotype and activity.  
 
• The differentiation of peripheral blood monocytes into macrophages was 
determined by cell morphological changes and changes to the receptor profile. 
Notably, differentiated macrophages expressed CD80, CD163 and CD206 (the 
mannose receptor) while their monocyte precursors did not 
 
• The MDMs demonstrated plasticity in their surface receptor expression following 
polarisation with IFNγ, LPS and IL-4. Notably, polarisation with IFNγ and LPS 
increased expression of pro-inflammatory marker CD80, while IL-4 polarisation 
increased expression of pro-resolution marker CD163 
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• The use of fluorescent polystyrene microspheres as a phagocytic target for the 
MDMs, caused a coincidence effect signal when the MDMs were analysed using flow 
cytometry. Using cytochalasin D as a negative control for phagocytosis showed little 
effect of reducing the microsphere signal in MDMs  
 
• The use of fluorescently labelled E. coli and apoptotic neutrophils served as more 
biologically relevant and effective targets for a phagocytic assay system. Using flow 
cytometry, it was possible to quantify phagocytic cells in the MDM population and 
block the phagocytic signal using cytochalasin D 
 
• A time-series of a macrophage and apoptotic neutrophil co-culture using confocal 
microscopy and a heated stage allowed for the study of macrophage/target 
interactions in real time. This system was developed further by using spinning disc 
confocal microscopy and labelling apoptotic neutrophil targets with a pH sensitive 
dye for easier tracking of phagocytic activity 
 
• The flow cytometry phagocytosis assay system was used to track the modulation 
of phagocytic activity of macrophages by pharmacological agents. The 
glucocorticoid Dexamethasone augmenting efferocytosis of apoptotic neutrophils, 
while the Nrf-2 agonist sulforaphane did not increase phagocytosis of bacteria 
 
6.1.2 Chapter four summary  
 
Chapter four sought to develop profiling of macrophages based on receptor 
expression, by using a fluorescent nanobody targeting the MR that could be used for 
in vivo studies.  
 
• The MR-nanobody, following conjugation to sulphonated Cyanine 5 dyes, was able 
to label MDMs with a high signal to noise ratio, using nanomolar amounts of 
nanobody with no wash step required  
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• The staining pattern of the MR-nanobody when imaged with confocal microscopy 
was similar to a commercial anti-CD206 mAb 
 
• The MR-nanobody could selectively label MDMs over monocytes and A549 cells 
(acting as a alveolar epithelial cell model) but showed off-target labelling of human 
neutrophils, albeit a subset of neutrophils that may be activated or even necrotic 
 
• The MR-nanobody labelled primary human alveolar macrophages from a broncho-
alveolar lavage sample, demonstrating potential use to label AMs in vivo 
 
• Stimulating MDMs with IFNγ, LPS and IL-4 did not alter the labelling 
characteristics of the MR-nanobody, suggesting it could not differentiate between 
polarised macrophages 
 
• Studies into the labelling characteristics of the MR-nanobody showed that it 
initially labelled the membrane of macrophages, before being internalised into the 
cytoplasm. Cytochalasin D reduced the amount of labelling by the MR-nanobody 
 
• Using excess mannan as a known MR ligand did not block MR-nanobody labelling 
and provided inconclusive results about the target specificity of the MR-nanobody 
 
• The MRC1 gene, coding for the MR, was successfully transfected into CHO cells, as 
determined by flow cytometric labelling with a anti-CD206 mAb, but this did not 
prompt labelling by the MR-nanobody following transfection  
 
6.1.3 Chapter five summary 
 
Chapter five focussed on the application of novel OEM platforms, designed to image 
in the alveolar space in situ, to profiling the phagocytic activity of macrophages. This 
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involved two systems: one using standard fluorescence intensity imaging to image 
phagocytic macrophages, and another utilising a greater detail of spectral analysis 
to image autofluorescent alveolar macrophages.  
 
• Versicolour, a fluorescence widefield OEM platform developed by the Proteus 
group (University of Edinburgh), was able to perform two-colour imaging of labelled 
MDMs and identify phagocytic cells based on fluorescence of separately labelled 
apoptotic neutrophils. Phagocytic cells were identified by fluorescence of pH-
sensitive pHrodo labelling of apoptotic neutrophils, the signal for which was blocked 
by cytochalasin D.  
 
• A novel OEM platform was developed by Helen Parker (University of Edinburgh) to 
enhance the contrast of spectrally similar objects via spectral ratio imaging: 
calculating specific spectral ratio values of objects determined by unique 
fluorescence emission profiles 
 
• The SR system could differentiate between the autofluorescence of alveolar 
macrophages and lung tissue by assigning different SR values due to distinct 
fluorescence emission spectra 
 
• The SR system could image phagocytic MDMs in an in vitro assay system, through 
detecting pHrodo signal of internalised E. coli. This signal was validated as indicative 
of phagocytosis due to blocking with cytochalasin D. 
 
• The SR system could image human alveolar macrophages in an in vitro setting 
based solely of autofluorescence but could not identify phagocytic cells due to a lack 
of pHrodo signal from phagocytic targets.  
 
• Using Syto-81 nucleic acid stain labelling of MDMs to model AM autofluorescence, 
the SR system showed potential to differentiate between phagocytic and non-
 143 
phagocytic macrophages even with spectrally similar fluorescence signals of Syto 81 
and pHrodo Green. However, cytochalasin D was not able to block what was 
assumed to be pHrodo signal, thereby not validating successful profiling of 
phagocytic cells.  
 
6.2 Limitations and Future Directions 
 
6.2.1 Modelling and profiling alveolar macrophages  
 
A prominent challenge for in vitro studying of macrophage phenotype activity is 
using a representative model for the macrophage subset that is the focus of the 
work- in the case of this thesis it was the alveolar macrophage. As discussed in more 
detail in chapter three, there is a great deal of heterogeneity in the phenotypes of 
different macrophage populations. The cell surface receptor expression profile of 
AMs is likely unique to that population and may not be clearly reflected by in vitro 
monocyte-derived macrophages or differentiated monocytic cell lines. Had it been 
possible to acquire more broncho-alveolar samples during this study, I would have 
sought to characterise in more detail the receptor expression profile of AMs. As 
these AMs would likely be from COPD patients, receptor profiling would therefore 
reflect AM receptor expression in COPD pathology. This would have helped validate 
the choice of receptor targets for probes to label AMs during COPD, as well as 
provide greater detail of phagocytic receptor expression on COPD AMs.  
 
One challenge of profiling primary AMs in vitro is the high levels of autofluorescence 
from these cells. When using optical imaging platforms to profile cell phenotype and 
activity, the AM autofluorescence can impede the use of fluorescent mAb to label 
surface receptors, or labelled targets for phagocytic activity. The purpose of some of 
the work in chapter five was to demonstrate how spectral ratio imaging can mitigate 
AM autofluorescence with in situ imaging systems, however optical systems with 
similar properties would be required for more detailed studies in vitro. There are now 
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spectral flow cytometry systems that would suit these studies. Spectral flow 
cytometry takes advantage of multispectral and hyperspectral analysis of cells, 
gaining a detailed spectral profile on a single cell basis. These systems can define the 
spectral fingerprint of an autofluorescent AM and increase the detection of 
fluorescent mAb, other probes, or labelled phagocytic targets. These in vitro systems 
would improve understanding of COPD AM phagocytic activity. By mitigating AM 
autofluorescence in the detection of phagocytic targets, more detailed studies on 
the phagocytic defect of COPD AMs could be performed, including their response to 
pharmacological manipulation in vitro.  
 
Alternative bench-top imaging platforms are also available to mitigate AM 
autofluorescence, such as confocal microscopes which utilise fluorescence lifetime 
as well as intensity. One such system has been in development by the Proteus Group 
(University of Edinburgh) which encompasses an inverted microscope with a heated 
stage. The use of FLIM has become an attractive modality in the study of 
macrophages 243,245. This bench-top FLIM platform would allow dynamic FLIM 
imaging of macrophage phagocytosis for the first time. This could open up new 
avenues for profiling macrophages based on their optical fingerprint (fluorescence 





6.2.2 Use of macrophage probes for in vivo use  
  
The study of potential receptor probes to be used in vivo for AMs would also require 
detailed analysis of the receptor profiles of AMs during COPD, in order to validate 
target expression for the probe. In the context of this thesis, the level of MR 
expression on COPD AMs was not established (though the MR-nanobody did label 
isolated COPD AMs). The suitability of the MR, or any other receptor as a probe 
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target, should be evaluated in line with the ultimate purpose of a macrophage probe. 
For example, the mannose receptor is a suitable target to selectively label 
macrophages over other cell types, though may not provide further phenotypic 
information. In the literature, the MR is often considered a marker for macrophages 
in an anti-inflammatory state. However, from my studies of MDMs in vitro, the 
expression of the MR remained heterogenous following MDM differentiation with 
distinct polarising agents or pharmacological treatment. This indicated that the MR 
may not be the most suitable receptor probe target for profiling the activated state 
of a macrophage.  
 
Another consideration not explored in the work in chapter four was the effect on 
macrophage function probe labelling had. The MR-nanobody selectively labelled 
macrophages and appeared to be actively internalised by the cells. Further work 
should focus on if the MR-nanobody altered the phenotype or function of labelled 
macrophages. This should include evaluating changes to receptor expression, cell 
viability, and phagocytic activity following MR-nanobody labelling.  
 
The end purpose of in vivo macrophage probes was to be used with OEM platforms 
for in situ labelling of macrophages. Therefore, the imaging characteristics of the 
MR-nanobody or other candidate probes with OEM platforms would be required. For 
example, the limit of detection (LoD) for the concentration of probe used in in vitro 
systems, using sensitive optical detection methods such as flow cytometry and 
confocal microscopy, may not align with the LoD of OEM platforms. In addition, the 
labelling characteristics with OEM platforms and the MR-nanobody should be 
carried out with model systems more relevant to the alveolar space. This could 
involve imaging labelled macrophages on ex vivo lung tissue, or in perfused whole 
lung models that have been established by the Proteus Group.  
 
6.2.3 OEM to profile macrophages in situ 
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While the use of OEM platforms to perform in situ profiling of macrophages can be 
a great asset to methods of experimental medicine, some limitations may hinder the 
development of these studies. A notable limitation is the small field of view (FOV) 
created by the bespoke imaging fibre bundles that allow for in situ imaging. Due to 
size restrictions, the total FOV in these bundles is ~450 µm across. This would 
ultimately provide a limited area to profile macrophage activity in the alveolar space, 
resulting in a likely unrepresentative population of cells and an increased chance of 
missing important events such as phagocytosis. As this technology progresses, 
there will be approaches taken to overcome this limited FOV. Incorporating 
operator-controlled distal tip steering of the fibre imaging bundle will provide 
greater control of regional exploration in the alveolar space. This could allow 
mosaicking of multiple FOV to generate a more representative picture of an AM 
population.  
 
As OEM platforms become paired with optical probes or phagocytic targets to 
profile macrophages in situ, effective quantification of these fluorescence-based 
assays would be required to provide objective information of macrophage activity. 
The development of machine learning algorithms to detect labelled bacteria in the 
human lung following OEM imaging has been previously described 264. Similar 
approaches would be required with the profiling of macrophages in the alveolar 
space to extract a detailed optical fingerprint of macrophage activity in this space.  
 
As has been described in chapter five of this thesis, the main challenge of optical 
imaging in the human lung in situ is the high amounts of autofluorescence - from 
lung tissue and AMs – that could interfere with detection of optical probes and 
labelled phagocytic targets. The potential of the SR system described in chapter five 
and in a published study represents the ability to mitigate this autofluorescence in 
the lung and carry out multiplexed imaging of multiple fluorophores, even when 
they are spectrally similar. Given more time, I would have expanded the work in 
chapter five to demonstrate the multiplexing capabilities of the SR system, 
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performing imaging on human lung tissue, combined with autofluorescent cells with 
the MR-nanobody or phagocytic targets. This would show it is possible to overcome 
the multiplexing limitations of optical imaging in the alveolar space. Building on this, 
the work would progress onto using a perfused whole lung model to demonstrate 
the ability to perform real time profiling of macrophage phenotype and phagocytic 
activity in situ using a model system as biologically relevant as it can be to image in 
a live human lung. Such an assay system would be of high value to monitoring the 
response of AMs to pharmacological stimulation while still in the 3D alveolar space, 




The work in this thesis has provided the foundation to profiling macrophages in the 
human lung. Taking forward optical assay systems, designed to profile the receptor 
expression of macrophages and their phagocytic activity, and combining them with 
optical probes and imaging platforms capable of performing in situ imaging, it will 
be possible to expand understanding of macrophage activity in the human lung. 
These methodologies could ultimately become an influential approach of 
experimental medicine to profile AMs in situ and monitor pharmaceutical effects on 
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